Tag Archive for: Caboolture urologist

Robotic-Assisted Enucleation of the Large Benign Prostate / Robotic-Assisted Simple Prostatectomy RASP

/0 Comments/in , /by

A modern surgical option for very large benign prostate enlargement

Benign prostatic hyperplasia (BPH), or benign prostate enlargement, becomes increasingly common as men age. For many men, symptoms can initially be controlled with medication or minimally invasive treatments. However, when the prostate becomes very large, simply creating a small channel through the prostate may not provide the durable result required.

Robotic-assisted simple prostatectomy (RASP), sometimes described as robotic-assisted adenoma enucleation, is designed to remove the bulk of the obstructing benign prostate tissue while leaving the outer prostate capsule behind.

Importantly, this is not the same operation as a robotic radical prostatectomy for prostate cancer. In a radical prostatectomy, the entire prostate and seminal vesicles are removed. In robotic simple prostatectomy, only the enlarged central adenoma responsible for urinary obstruction is removed.

Current guidelines recognise robotic-assisted simple prostatectomy as an established surgical option for men with large to very large prostates.

Why does a large prostate cause problems?

The prostate surrounds the urethra immediately below the bladder.

As benign prostate tissue enlarges, it can compress and distort the urethra. The bladder then has to work increasingly hard to push urine through this narrowed channel.

Symptoms may include:

  • Weak urinary stream
  • Hesitancy or difficulty starting urination
  • Straining
  • Intermittent urinary flow
  • A feeling that the bladder has not emptied properly
  • Frequent urination
  • Urgency
  • Getting up repeatedly at night to urinate
  • Acute or chronic urinary retention
  • Recurrent urinary infections
  • Bladder stones
  • Blood in the urine
  • Progressive deterioration of bladder function
  • In severe cases, obstruction affecting the kidneys

Surgery is particularly appropriate when significant symptoms persist despite conservative or medical therapy, or when BPH produces complications such as recurrent urinary retention, infection, bladder stones, recurrent bleeding or renal impairment.

When is robotic prostate enucleation considered?

Robotic-assisted enucleation is particularly attractive when the prostate is large or very large.

There is no magical prostate volume at which the robot suddenly becomes necessary. Treatment needs to be individualised according to prostate anatomy, symptoms, bladder function, other medical conditions and the surgeon’s expertise.

In practice, robotic simple prostatectomy is most commonly considered for prostates approximately 80–100 mL or larger, and can be particularly useful for extremely large glands well beyond 150–200 mL.

The EAU describes simple prostatectomy as a treatment primarily for substantially enlarged prostates, traditionally above approximately 80–100 mL.

Typical indications include:

  • Severe lower urinary tract symptoms caused by a very large prostate
  • Recurrent urinary retention
  • Dependence on an indwelling or intermittent urinary catheter
  • Failure or intolerance of BPH medications
  • Recurrent bladder infections associated with obstruction
  • Recurrent bleeding from a large vascular prostate
  • Bladder stones associated with prostate obstruction
  • Very high residual urine volumes
  • Progressive bladder dysfunction caused by obstruction
  • Upper urinary tract or renal consequences from longstanding obstruction
  • A very large median lobe protruding into the bladder
  • A very large prostate where conventional TURP would be impractical or require extensive resection

Robotic surgery can also be useful when another bladder procedure, such as removal of large bladder stones or repair of a bladder diverticulum, needs to be performed at the same operation.

How is the operation performed?

The procedure is usually performed under a general anaesthetic using a robotic surgical platform.

Several small incisions are made in the abdomen. Robotic instruments and a high-definition three-dimensional camera are introduced through these ports.

The surgeon remains completely in control of the operation. The robot does not perform the surgery independently. Rather, it translates the surgeon’s hand movements into extremely precise movements of miniature instruments inside the body.

There are several variations of robotic simple prostatectomy, including transvesical, transcapsular, extraperitoneal and newer single-port approaches.

Finding the natural plane

The principle of the operation is beautifully simple.

The enlarged prostate consists of an inner adenoma surrounded by the compressed outer prostate or surgical capsule.

The surgeon identifies the natural anatomical plane between these layers and carefully separates the adenoma from the capsule.

Think of removing the flesh of an orange while deliberately leaving the peel behind. 🍊

The obstructing prostate adenoma is progressively freed from its surrounding capsule and removed.

Bleeding points can be precisely controlled using robotic suturing and cautery. The remaining prostate cavity and bladder are then reconstructed according to the surgical technique being used.

The removed prostate tissue is sent to pathology for examination.

What happens to the prostate afterwards?

The prostate is not completely removed.

The peripheral prostate and capsule remain in the body.

This is important because:

  1. PSA does not normally fall to zero after the operation.
  2. The remaining prostate tissue can still develop prostate cancer in the future.
  3. Appropriate PSA surveillance and prostate cancer screening should therefore continue.

Occasionally, previously unsuspected prostate cancer may also be identified when the removed adenoma is examined by the pathologist.

What happens to urinary flow?

Removing the obstructing adenoma creates a very large channel between the bladder and the remaining prostatic urethra.

Most appropriately selected patients experience substantial improvements in:

  • Urinary flow
  • Bladder emptying
  • Residual urine
  • Urinary symptoms
  • Quality of life

Studies of laparoscopic and robotic simple prostatectomy demonstrate substantial improvements in urinary symptom scores and maximum urinary flow rates.

For a man who has spent years waiting for his bladder to negotiate with a very large prostate, the improvement in flow can be rather dramatic.

The urinary catheter

A urinary catheter is placed during the operation.

This allows urine to drain freely while the bladder and prostate cavity heal. Depending upon the operation and surgeon’s technique, continuous bladder irrigation may initially be used to prevent blood clots accumulating within the bladder.

How long does the catheter stay in?

Catheter duration varies considerably between surgical techniques and centres.

Following conventional robotic simple prostatectomy, a catheter commonly remains for approximately 5–10 days, although some contemporary techniques permit earlier removal.

Recent comparative studies report catheter durations around 5–11 days following RASP, although protocols vary substantially between surgeons and institutions.

Laser enucleation procedures such as HoLEP generally permit earlier catheter removal. A 2026 meta-analysis comparing robotic simple prostatectomy with laser enucleation found that catheterisation was approximately 3.5 days shorter after laser enucleation.

In some patients a cystogram may be performed before catheter removal, particularly when extensive bladder reconstruction has been performed.

What can I expect after catheter removal?

The first few days can be a little lively.

Patients may experience:

  • Urinary frequency
  • Urgency
  • Mild burning
  • Blood in the urine
  • Passing occasional small clots
  • Temporary leakage
  • A sudden improvement in urinary flow

Urinary frequency and urgency can take longer to settle if the bladder has been struggling against obstruction for many years.

Removing the obstruction fixes the prostate problem, but an ageing or overactive bladder does not necessarily receive the memo immediately.

Advantages of robotic-assisted enucleation

For appropriately selected men with very large prostates, potential advantages include:

Removal of a very large amount of obstructing tissue

Rather than simply widening the channel, the procedure anatomically removes most of the transition-zone adenoma.

Suitable for extremely large prostates

The technique is relatively independent of prostate size and can be particularly useful when the prostate is enormous.

Excellent visualisation

The robotic system provides magnified three-dimensional vision and excellent access to the bladder and prostate.

Precise control of bleeding

Robotic suturing allows individual bleeding vessels to be identified and controlled.

Lower morbidity than traditional open simple prostatectomy

Compared with open surgery, robotic simple prostatectomy generally produces less blood loss, lower transfusion rates and shorter hospitalisation, although robotic operations can take longer.

Simultaneous bladder surgery

Large bladder stones, selected bladder diverticula and other pathology can potentially be managed during the same operation.

Durable removal of obstruction

Because most of the obstructing adenoma is removed, substantial recurrent obstruction from regrowth is uncommon.

Possible complications

As with any major surgical procedure, complications can occur.

Bleeding

Some bleeding is expected because the prostate has a rich blood supply.

Blood transfusion is uncommon with modern robotic techniques but remains possible, particularly with exceptionally large glands, anticoagulant therapy or significant postoperative bleeding.

Rarely, significant bleeding may require return to theatre.

Urinary infection

A urinary infection can occur following surgery or while the catheter is present.

Symptoms can include fever, burning, cloudy urine or feeling systemically unwell.

Blood clots and catheter blockage

Bleeding can produce clots within the bladder.

Continuous bladder irrigation may therefore be used during the early postoperative period. Occasionally a catheter may require irrigation or replacement, and rarely clot evacuation under anaesthesia is necessary.

Temporary urinary incontinence

Some men experience temporary urinary leakage following catheter removal.

This generally improves as the external urinary sphincter adapts to the newly unobstructed urinary channel.

Pelvic floor exercises may assist recovery.

Persistent severe stress urinary incontinence is uncommon but remains a recognised complication.

Urinary urgency

Urgency, frequency and urge incontinence may temporarily become more noticeable after surgery.

Men who had longstanding bladder obstruction may have developed detrusor overactivity or impaired bladder function. Consequently, bladder symptoms may take weeks or months to settle and occasionally require additional treatment.

Bladder neck contracture

Scar tissue can occasionally develop around the bladder outlet.

If significant, this may require an endoscopic procedure to reopen the channel.

Urethral stricture

Scar tissue can develop within the urethra following instrumentation or catheterisation.

This is uncommon but may require dilatation, urethrotomy or, rarely, reconstructive surgery.

Injury to surrounding structures

Rare complications include injury to the:

  • Bladder
  • Ureteric openings
  • Ureter
  • Rectum
  • Bowel
  • Blood vessels

Major complications requiring additional surgery are uncommon but possible.

General surgical complications

These include:

  • Deep vein thrombosis
  • Pulmonary embolism
  • Chest infection
  • Cardiovascular complications
  • Anaesthetic complications
  • Port-site hernia
  • Wound infection

Appropriate preventative measures are used according to individual patient risk.

What happens to ejaculation?

This deserves particular emphasis.

Retrograde or absent ejaculation is very common.

During normal ejaculation, the bladder neck closes and semen travels forward through the urethra.

After removal of a large prostate adenoma, this mechanism is altered. Semen may pass backwards into the bladder or there may be very little visible ejaculate.

The sensation of orgasm usually remains, but ejaculation is frequently dry or markedly reduced.

This can significantly affect fertility and should be discussed before surgery in men who may wish to father children.

What about erections?

Robotic simple prostatectomy is different from radical prostatectomy for prostate cancer.

The prostate capsule and surrounding neurovascular structures are generally preserved.

Consequently, erectile dysfunction is not an inevitable consequence of robotic simple prostatectomy.

Temporary deterioration can occur following any major pelvic operation, particularly in older men with pre-existing vascular or erectile problems, but many men maintain their preoperative erectile function.

Will the prostate grow back?

One of the major advantages of anatomical enucleation is its durability.

The majority of the obstructing adenoma is physically removed rather than simply compressed or partially vaporised.

Some benign prostate tissue remains and can slowly enlarge over many years, so recurrent obstruction is possible, but clinically significant regrowth requiring repeat surgery appears uncommon.

Long-term RASP-specific retreatment data are less mature than data for older procedures because robotic simple prostatectomy is a newer technique. Studies nevertheless show durable functional improvement, and contemporary comparisons demonstrate similar symptom and flow improvements between RASP and anatomical endoscopic enucleation.

For perspective, long-term data for traditional open simple prostatectomy, which uses the same fundamental principle of adenoma enucleation, show endourological reintervention rates of approximately 3% at one year, 6% at five years and 8.8% at eight years. These figures should not be presented as RASP-specific recurrence rates, but they demonstrate the durability of complete adenoma enucleation.

Robotic enucleation versus HoLEP

Both procedures are excellent options for large prostates.

HoLEP removes the adenoma through the urethra using a holmium laser and subsequently morcellates the tissue within the bladder.

Robotic simple prostatectomy approaches the prostate through the abdomen and bladder or prostate capsule.

Recent evidence suggests that both produce substantial and broadly comparable improvements in urinary symptoms, urinary flow and bladder emptying.

HoLEP generally has the advantages of:

  • No abdominal incisions
  • Shorter catheterisation
  • Shorter hospitalisation in many series
  • Very low blood loss
  • Excellent durability

Robotic surgery may be particularly attractive when:

  • The prostate is exceptionally large
  • There are very large bladder stones
  • Concomitant bladder reconstruction is required
  • Prostate anatomy makes a robotic approach advantageous
  • The surgeon has extensive robotic experience
  • Endoscopic enucleation expertise is not available

The best procedure is therefore not determined by prostate volume alone.

Robotic enucleation versus TURP

TURP remains an excellent operation for appropriately sized prostates, but attempting to resect an enormous prostate piece by piece can become a lengthy undertaking.

Robotic enucleation removes the adenoma anatomically and is therefore particularly suited to large-volume disease.

For very large prostates, current guidelines support simple prostatectomy and anatomical endoscopic enucleation rather than assuming conventional TURP is the optimal treatment.

Recovery after robotic prostate enucleation

Hospital stay varies according to the technique, prostate size and individual recovery.

After discharge, patients are generally encouraged to walk regularly but avoid strenuous exercise and heavy lifting during the early healing period.

Blood in the urine may come and go for several weeks, particularly after physical activity.

Patients should seek medical attention for:

  • Inability to pass urine
  • A catheter that stops draining
  • Heavy persistent bleeding
  • Large blood clots
  • Fever or chills
  • Increasing abdominal pain
  • Chest pain or shortness of breath
  • Significant calf swelling or pain

Is robotic-assisted enucleation right for every large prostate?

No.

The decision should take into consideration:

  • Prostate volume and anatomy
  • Severity of urinary symptoms
  • Urinary flow and residual urine
  • Bladder function
  • Previous urinary retention
  • Presence of bladder stones or diverticula
  • PSA and prostate cancer risk
  • Previous prostate surgery
  • Anticoagulant or antiplatelet medication
  • General health
  • Anaesthetic risk
  • Patient priorities regarding ejaculation and sexual function
  • Availability and experience of the treating surgeon

Alternatives may include HoLEP, other forms of endoscopic enucleation, bipolar TURP, GreenLight laser surgery, Aquablation, prostate artery embolisation, medical therapy or continued observation, depending upon prostate size, anatomy and the individual patient’s circumstances.

The bottom line

For men with a very large benign prostate causing significant urinary obstruction, robotic-assisted prostate enucleation offers a powerful and durable surgical solution.

Rather than trimming away small amounts of tissue, the surgeon follows the natural anatomical plane around the prostate adenoma and removes the obstructing tissue almost in its entirety.

The trade-off is that this remains a significant operation, usually requiring several days of catheterisation and a period of recovery. Retrograde or absent ejaculation should be expected, and complications including bleeding, infection, temporary incontinence, bladder neck contracture and urethral stricture can occur.

For the appropriately selected patient, however, the combination of substantial adenoma removal, excellent urinary flow improvement, low retreatment requirements and the precision of robotic surgery makes robotic-assisted simple prostatectomy an important contemporary option for the very large benign prostate.

This information is intended for general patient education and does not replace individual assessment and advice from a urologist.

TURP for Benign Prostatic Hyperplasia (BPH)

/0 Comments/in , /by

The Traditional Benchmark for Prostate Surgery

For decades, Transurethral Resection of the Prostate (TURP) has been one of the most established surgical treatments for urinary obstruction caused by benign prostatic hyperplasia (BPH).

Although newer technologies such as GreenLight laser vaporisation, HoLEP, Aquablation, Rezūm and robotic-assisted simple prostatectomy/enucleation have expanded the treatment menu, TURP remains an important benchmark against which many newer procedures are compared.

The basic principle is refreshingly straightforward: remove the obstructing prostate tissue from the inside and create a wider channel for urine to pass through.

What is BPH?

Benign prostatic hyperplasia is the non-cancerous enlargement of the prostate that commonly occurs as men age.

As the prostate enlarges around the urethra, it may progressively restrict urinary flow. Symptoms can include:

  • A weak urinary stream
  • Difficulty starting urination
  • Straining to urinate
  • Intermittent or stop-start flow
  • Feeling that the bladder has not emptied completely
  • Urinary frequency
  • Urgency
  • Getting up several times at night to urinate
  • Acute or chronic urinary retention

Importantly, prostate size and symptoms do not always travel together. A relatively modest prostate can produce significant obstruction, while some very large prostates cause surprisingly little trouble.

What is a TURP?

TURP stands for Transurethral Resection of the Prostate.

There is no external incision.

A specialised telescope called a resectoscope is passed through the urethra and into the prostate. A small electrical loop is then used to progressively remove pieces of obstructing prostate tissue.

Think less “removing the prostate” and more opening up the tunnel through it.

The outer portion of the prostate remains behind. TURP is therefore very different from a radical prostatectomy, where the entire prostate is removed to treat prostate cancer.

The removed prostate tissue is usually sent to pathology for examination.

Monopolar versus Bipolar TURP

There are two principal forms of TURP.

Monopolar TURP

Traditional monopolar TURP uses electrical current passing between the resection loop and a grounding pad on the patient.

It requires non-conductive irrigation fluid during surgery.

One uncommon but potentially serious complication is TUR syndrome, where excessive absorption of irrigation fluid can cause dilution of the blood sodium concentration.

Bipolar TURP

Modern bipolar TURP allows the electrical circuit to remain localised around the resection electrode and permits the use of normal saline irrigation.

This substantially reduces the risk of TUR syndrome and has made TURP safer, particularly when longer operating times are required.

For this reason, bipolar TURP has become widely used in contemporary practice.

Who Should Consider TURP?

TURP is generally considered when urinary symptoms from benign prostate enlargement are sufficiently troublesome or when BPH begins causing complications.

Common indications include:

Moderate to severe lower urinary tract symptoms

Men whose symptoms remain troublesome despite medication, or who prefer definitive surgical treatment, may benefit from TURP.

Recurrent urinary retention

Repeated episodes requiring catheterisation suggest significant bladder outlet obstruction.

Catheter-dependent urinary retention

Some men become unable to urinate without a catheter. TURP may restore spontaneous voiding, although success also depends on how well the bladder muscle continues to function.

Recurrent urinary tract infections

Incomplete bladder emptying can contribute to recurrent infections.

Bladder stones

Persistent obstruction and residual urine may encourage bladder stone formation.

Recurrent bleeding from an enlarged prostate

Significant or recurrent haematuria attributable to BPH can occasionally be an indication for surgery.

Progressive bladder dysfunction

Longstanding obstruction may cause bladder wall thickening, diverticula, increasing residual urine and eventually impaired bladder contractility.

Kidney impairment or hydronephrosis due to bladder outlet obstruction

This represents an important indication for relieving the obstruction.

What Size Prostate is Suitable for TURP?

TURP has traditionally been particularly suitable for prostates in approximately the 30–80 mL range.

The 2026 European Association of Urology guideline continues to regard TURP as a standard surgical treatment for appropriately selected men with moderate-to-severe lower urinary tract symptoms and prostates in this general size range.

Larger prostates can certainly be treated by TURP, particularly in experienced hands, but increasing gland size means:

  • Longer operating time
  • Greater bleeding risk
  • More tissue requiring resection
  • Potentially incomplete adenoma removal
  • Greater likelihood of requiring staged surgery

For substantially larger glands, anatomical enucleation procedures such as HoLEP or, in selected patients, robotic-assisted simple prostatectomy/enucleation may offer advantages because they remove a greater proportion of the obstructing adenoma.

When Might TURP Not Be Appropriate?

There are relatively few absolute contraindications to TURP, but there are circumstances where surgery should be delayed or another approach considered.

Active urinary infection

A symptomatic urinary tract infection should generally be treated before elective surgery because instrumentation can increase the risk of sepsis.

Uncorrected bleeding disorder

Significant coagulopathy requires appropriate assessment and management before surgery.

Anticoagulant and antiplatelet medications require individualised management. They should never simply be stopped without medical advice, as the risk of bleeding must be balanced against the patient’s cardiovascular or thromboembolic risk.

Severe urethral stricture disease

If a resectoscope cannot safely pass through the urethra, the urethral problem may require treatment first or an alternative surgical strategy may be required.

Very large prostate

This is not an absolute contraindication, but procedures such as HoLEP or robotic/open simple prostatectomy may be more appropriate for some very large glands.

Poor bladder contractility

Not every weak stream is caused purely by the prostate.

A bladder that has become significantly underactive may still empty poorly even after an excellent TURP.

This distinction can be particularly important in men with chronic urinary retention, neurological disease, diabetes or very large residual urine volumes. Urodynamic pressure-flow studies can occasionally help determine whether obstruction, impaired bladder contraction, or a mixture of both is responsible.

What Happens During TURP?

TURP is usually performed under either general or spinal anaesthesia.

The resectoscope is passed through the urethra to the prostate.

The surgeon progressively removes obstructing prostate tissue until a wide channel has been created between the bladder and the urethra.

Bleeding points are cauterised during the procedure.

At completion, a urinary catheter is usually inserted. Continuous bladder irrigation may be used initially to prevent blood clots accumulating inside the bladder.

Most patients remain in hospital until the urine has cleared sufficiently and the catheter can safely be removed.

What Should I Expect Afterwards?

It is common to experience:

  • Blood in the urine
  • Burning or stinging during urination
  • Increased urinary frequency
  • Urgency
  • Temporary difficulty controlling urgency
  • Intermittent blood or small clots for several weeks

The urinary stream often improves relatively quickly, while frequency and urgency can take longer to settle.

This is particularly true when the bladder has been fighting obstruction for many years. Removing the obstruction does not necessarily make an irritable bladder forget its old habits overnight.

Risks and Complications of TURP

TURP is well established and generally safe, but it remains an operation and complications can occur.

Bleeding

Some bleeding is expected.

Occasionally bleeding may be sufficient to require:

  • Prolonged bladder irrigation
  • Blood transfusion
  • Return to theatre for evacuation of blood clots and control of bleeding

Significant transfusion is much less common with contemporary techniques than historically.

Infection

Urinary tract infection can occur following TURP.

Patients with long-term catheters, recurrent infections or significant residual urine may have a higher risk.

Rarely, infection can progress to urosepsis.

Temporary Urinary Retention

Some patients cannot urinate immediately after catheter removal.

The catheter may need to be reinserted temporarily.

This is more likely when the bladder muscle has become weak following longstanding obstruction.

Retrograde Ejaculation

One of the most important long-term consequences of TURP is retrograde ejaculation.

Normally, the bladder neck closes during ejaculation so semen travels forwards through the penis.

After TURP, the bladder neck may remain open during ejaculation. Semen therefore travels backwards into the bladder and is subsequently passed harmlessly with the urine.

The orgasmic sensation is usually preserved, but little or no semen may emerge from the penis.

Retrograde ejaculation is common after conventional TURP and should be discussed before surgery, particularly in younger men concerned about fertility or preservation of ejaculation.

Erectile Dysfunction

Most men do not develop erectile dysfunction simply because they have undergone TURP.

Some men report changes in erectile function after surgery, while others notice improvement associated with better sleep, fewer urinary symptoms and improved general wellbeing.

Age, cardiovascular disease, diabetes, medications and pre-existing erectile dysfunction frequently have a greater influence on erections than the TURP itself.

Urinary Incontinence

Temporary urgency and urge leakage can occur during recovery.

Persistent significant urinary incontinence following uncomplicated TURP is considerably less common.

A contemporary systematic review and meta-analysis of randomised TURP studies reported an overall incontinence rate of approximately 8%, although this includes differing definitions and follow-up intervals and therefore should not be interpreted as an 8% rate of permanent severe incontinence.

Urethral Stricture After TURP

One of the important delayed complications is a urethral stricture.

A stricture is scar tissue that progressively narrows the urethra.

Symptoms may include:

  • A gradually weakening urinary stream
  • Spraying or splitting of the stream
  • Straining
  • Incomplete bladder emptying
  • Recurrent urinary infections
  • Urinary retention

The reported rate varies considerably between studies.

The EAU urethral stricture guideline reports urethral stricture rates following monopolar or bipolar TURP of approximately 1.7–11.7%, reflecting differences in surgical technique, instrumentation, follow-up and definitions.

A more recent systematic review of randomised TURP studies found an overall urethral stricture rate of approximately 3%.

For patient counselling, therefore, a reasonable practical message is:

Urethral stricture occurs in roughly 2–5% of contemporary TURP patients in many series, although reported rates vary more widely.

Potential contributing factors include the diameter of the resectoscope, duration of surgery, urethral trauma, postoperative catheterisation and other technical factors.

A stricture may be treated with urethral dilatation, endoscopic urethrotomy or, for more complex or recurrent strictures, urethroplasty.

Bladder Neck Contracture

Scar tissue can also develop at the bladder neck following TURP.

This is called bladder neck stenosis or bladder neck contracture.

The EAU guideline reports rates following TURP ranging approximately 2.4–9.7%, although contemporary rates vary considerably according to technique and patient population.

It can produce symptoms very similar to recurrent BPH and may require an endoscopic bladder neck incision or resection.

Can the Prostate Grow Back After TURP?

Yes, but perhaps “grow back” is slightly misleading.

TURP removes the obstructing inner portion of the prostate but does not remove the entire prostate gland.

Remaining benign prostate tissue can therefore enlarge over subsequent years.

Some men eventually develop recurrent obstruction and require another operation.

Importantly, not every patient who develops recurrent urinary symptoms has recurrent BPH. Other causes include:

  • Urethral stricture
  • Bladder neck contracture
  • Overactive bladder
  • Underactive bladder
  • Recurrent adenoma
  • Prostate cancer

Assessment is therefore preferable to simply assuming that “the prostate has grown back.”

What is the Redo Rate After TURP?

TURP provides durable symptom improvement for most men, but reoperation becomes more common with increasing follow-up.

A large systematic review involving 119 studies and more than 130,000 patients estimated TURP reoperation rates of approximately:

Time after TURP Reoperation rate
1 year 4.0%
2 years 5.0%
3 years 6.0%
5 years 7.7%

Longer-term population data also demonstrate the durability of TURP. An Austrian nationwide analysis cited by the EAU found actual repeat TURP rates of approximately 2.4% at one year, 6.1% at five years and 8.3% at eight years. When procedures for urethral stricture and bladder neck stenosis were also included, the overall retreatment rate reached approximately 12.7% at eight years.

These figures highlight an important distinction:

“Redo TURP” and “reoperation after TURP” are not necessarily the same thing.

A subsequent procedure might be required because of recurrent prostate obstruction, but it may instead be required to treat a urethral stricture or bladder neck contracture.

TUR Syndrome

Traditional monopolar TURP carries a small risk of TUR syndrome, caused by absorption of large volumes of non-saline irrigation fluid. This is a serious complication occasionally requiring an ICU admission as it can cause brain swelling.

This can result in:

  • Low blood sodium
  • Nausea and vomiting
  • Confusion
  • Blood pressure changes
  • Neurological disturbances
  • Cardiovascular complications

Modern bipolar TURP using saline irrigation has dramatically reduced this particular complication.

Does TURP Cause Prostate Cancer?

No.

BPH and prostate cancer are different diseases.

However, because TURP only removes part of the prostate, prostate cancer can still develop in the remaining gland.

Appropriate PSA surveillance and prostate assessment may therefore still be required after TURP.

Occasionally, unsuspected prostate cancer is discovered when TURP tissue is examined by the pathologist.

Advantages of TURP

TURP remains popular because it offers several important advantages:

  • Long-established procedure
  • Excellent improvement in urinary flow
  • Significant improvement in urinary symptoms
  • No external incision
  • Widely available
  • Tissue is obtained for pathological examination
  • Durable results
  • Particularly effective for appropriately selected medium-sized prostates
  • Extensive long-term outcome data

Despite the arrival of numerous newer technologies, TURP remains an important reference standard for surgical treatment of BPH. Long-term studies demonstrate sustained improvement in urinary symptoms and flow.

Disadvantages of TURP

Potential disadvantages include:

  • Anaesthetic and surgical risks
  • Bleeding
  • Catheterisation and hospital admission
  • Retrograde ejaculation
  • Temporary urinary urgency
  • Infection
  • Urethral stricture
  • Bladder neck contracture
  • Small risk of persistent incontinence
  • Possibility of future retreatment
  • Less suitable than anatomical enucleation for some very large prostates

TURP versus Modern BPH Surgery

TURP remains highly effective, but it is no longer the only surgical option.

Depending on prostate size, anatomy, medications, general health and the importance of preserving ejaculation, alternatives may include:

  • GreenLight laser vaporisation
  • HoLEP
  • Aquablation
  • Rezūm water-vapour therapy
  • Prostatic urethral lift
  • Other minimally invasive surgical therapies
  • Robotic-assisted simple prostatectomy or adenoma enucleation

Long-term comparisons increasingly suggest that anatomical endoscopic enucleation procedures can achieve lower retreatment rates than TURP in appropriately selected patients, particularly with larger glands.

There is therefore no single “best prostate operation” for every patient.

The aim is to match the procedure to the prostate, bladder and priorities of the man attached to them.

The Bottom Line

TURP remains one of the most proven and effective operations for benign prostate obstruction.

It can provide substantial and durable improvement in urinary flow and lower urinary tract symptoms, particularly in men with appropriately sized prostates and confirmed bladder outlet obstruction.

Patients should nevertheless understand the potential longer-term complications. Urethral stricture is generally reported in the low single-digit percentages in contemporary studies, although published rates range more widely. Repeat intervention becomes progressively more likely with longer follow-up, with pooled data suggesting a reoperation rate of approximately 7–8% by five years.

TURP may be the old workhorse of BPH surgery, but it has not wandered off to the retirement paddock just yet. For the right prostate and the right patient, it remains a highly effective treatment.

Important Information

This information is intended for general patient education and does not replace individual medical advice. The most appropriate treatment for BPH depends on prostate size and anatomy, severity of obstruction, bladder function, medications, general health, sexual priorities and personal preferences. A consultation with a urologist can help determine whether TURP or an alternative treatment is most appropriate.

So, if you are having issues with your flow and you want to find out more about your options, come see your local Brisbane and Caboolture urologist, Uro-Jo for advice.

Laser Vaporisation for Benign Prostate Enlargement

/0 Comments/in , /by

A Modern, Low-Bleeding Treatment for an Enlarged Prostate

Benign prostate enlargement, also called benign prostatic hyperplasia (BPH), is extremely common as men get older. As the prostate enlarges around the urethra, it can gradually restrict urinary flow, rather like slowly tightening a collar around the urinary pipe.

Symptoms may include:

  • A slow or weak urinary stream
  • Difficulty starting urination
  • Straining to urinate
  • Intermittent or stop-start flow
  • A feeling that the bladder has not emptied properly
  • Urinary frequency and urgency
  • Getting up several times at night to urinate
  • Episodes of urinary retention

Many men can initially be managed with lifestyle modification or medication. When symptoms become troublesome, complications develop, or medication is no longer effective or desirable, surgery may be considered.

One well-established minimally invasive surgical option is GreenLight laser photoselective vaporisation of the prostate (PVP).

What Is GreenLight Laser Prostate Surgery?

GreenLight PVP is an endoscopic procedure performed through the urethra. There are no abdominal incisions.

A telescope is passed through the urethra to the prostate. A specialised laser fibre is then used to progressively vaporise the obstructing prostate tissue and create a wider channel through which urine can flow.

Unlike TURP, where pieces of prostate tissue are physically cut away, GreenLight treatment predominantly converts the obstructing tissue into vapour while simultaneously sealing blood vessels.

The result is a combination of tissue removal and excellent haemostasis.

What Laser Is Used?

The GreenLight system uses a 532-nanometre green laser.

Modern GreenLight systems commonly use a lithium triborate (LBO) crystal to generate the 532 nm wavelength, with the contemporary high-powered platform delivering up to 180 watts.

Earlier systems included:

Generation Laser Maximum power
Early GreenLight KTP 80 W
GreenLight HPS LBO 120 W
GreenLight XPS LBO 180 W

The current European Association of Urology guideline describes the 180 W system as the contemporary standard platform for GreenLight PVP.

Why Is the Laser Green?

The colour is not merely decorative.

The 532 nm wavelength is strongly absorbed by haemoglobin, the pigment contained within red blood cells. It is much less strongly absorbed by water.

This property allows the laser energy to be preferentially absorbed by the vascular prostate tissue.

The laser has a relatively shallow tissue penetration of approximately 0.8 mm, producing rapid vaporisation while creating a limited zone of coagulation underneath the treated surface.

This gives GreenLight its two particularly useful characteristics:

Vaporisation + haemostasis

As prostate tissue is vaporised, small blood vessels are simultaneously coagulated.

This is why the operative field can remain remarkably clear and why GreenLight surgery generally produces less bleeding than traditional TURP.

Who May Benefit from GreenLight Laser Surgery?

GreenLight PVP may be considered for men with moderate to severe urinary symptoms caused by benign prostatic obstruction, particularly when conservative or medical treatment has not provided adequate relief.

Surgery may also be recommended when BPH results in complications such as:

  • Recurrent urinary retention
  • Dependence on a urinary catheter
  • Recurrent urinary tract infections associated with obstruction
  • Bladder stones
  • Recurrent visible haematuria attributable to BPH
  • Progressive bladder dysfunction
  • Significant residual urine
  • Upper urinary tract deterioration or renal impairment secondary to obstruction

Surgery is also reasonable when symptoms remain sufficiently troublesome despite medication, or when a patient does not wish to continue long-term medical therapy.

What Size Prostate Can Be Treated?

GreenLight PVP is particularly well established for prostates approximately 30–80 mL in volume.

The 2026 European Association of Urology guidelines recommend 532 nm GreenLight PVP as an alternative to TURP for men with moderate-to-severe LUTS and benign prostatic obstruction in this prostate-size range.

Larger prostates can certainly be treated by experienced GreenLight surgeons, but the operation becomes progressively more time-consuming as prostate volume increases.

Importantly, evidence supporting PVP in prostates above approximately 100 mL is less robust than the evidence supporting anatomical enucleation procedures such as HoLEP.

The AUA guideline similarly notes that PVP may be less effective in very large prostates and that retreatment becomes an increasingly important consideration.

For a very large prostate, HoLEP or robotic-assisted simple prostatectomy/enucleation may therefore provide more complete adenoma removal.

What Happens During GreenLight PVP?

The operation is usually performed under general or spinal anaesthesia.

A telescope is passed through the penis and urethra until the obstructing prostate is visualised.

The laser fibre is introduced through the telescope.

The surgeon progressively vaporises the obstructing prostate tissue, generally working from the bladder neck towards the apex of the prostate while carefully protecting the urinary sphincter.

The goal is not necessarily to remove the entire prostate.

Instead, the obstructing transition-zone tissue is removed sufficiently to create a wide, low-resistance urinary channel.

A urinary catheter is usually placed at the end of the operation.

Because bleeding is generally limited, catheterisation and hospitalisation can often be shorter than following conventional TURP.

Some appropriately selected patients can undergo the procedure as day surgery.

Advantages of GreenLight Laser Surgery

Less bleeding

This is arguably GreenLight’s greatest strength.

Because the 532 nm wavelength is absorbed by haemoglobin, tissue vaporisation and coagulation occur simultaneously.

Compared with TURP, studies have demonstrated lower transfusion rates and less bleeding.

Particularly useful when bleeding risk matters

GreenLight may be attractive in older patients or men with cardiovascular disease who require antiplatelet or anticoagulant medication.

The EAU guidelines specifically recognise GreenLight PVP as an option in selected patients receiving anticoagulant or antiplatelet therapy, although individual management of these medications still needs to be determined before surgery.

Shorter catheterisation

Many patients can have their catheter removed relatively quickly after surgery.

Shorter hospital stay

GreenLight surgery is frequently suitable for overnight or even day-case treatment in appropriately selected patients.

No external incision

The entire procedure is performed through the urethra.

No TUR syndrome

GreenLight PVP uses saline irrigation and does not carry the classical dilutional hyponatraemia or “TUR syndrome” associated with older monopolar TURP techniques.

Effective symptom improvement

GreenLight PVP can produce substantial improvements in:

  • Urinary flow
  • Bladder emptying
  • IPSS symptom scores
  • Quality of life

Randomised trials of contemporary GreenLight PVP have demonstrated symptom and flow improvements broadly comparable with TURP over short- to medium-term follow-up.

What Are the Side Effects?

Most men experience some temporary urinary irritation during the recovery period.

Burning or stinging when urinating

This is common initially and usually improves as the prostatic urethra heals.

Urinary frequency and urgency

The bladder may remain irritable for several weeks.

It is important to remember that removing the obstruction does not instantly reset a bladder that may have been struggling against that obstruction for many years.

Blood in the urine

Small amounts of bleeding can occur intermittently during healing, despite the excellent haemostatic properties of the laser.

Temporary difficulty urinating

Occasionally swelling after surgery means that the catheter needs to remain in place longer or needs to be reinserted.

Urinary infection

As with any endoscopic urinary procedure, urinary infection can occur.

Retrograde Ejaculation

One of the most important issues to discuss before surgery is ejaculation.

Following conventional GreenLight PVP, semen may travel backwards into the bladder rather than forwards through the penis during orgasm.

This is called retrograde ejaculation.

The orgasm usually remains present, but little or no semen may be produced.

This is particularly important for younger men concerned about fertility or preservation of ejaculation.

GreenLight should therefore not automatically be described as an “ejaculation-preserving” operation.

Does GreenLight Cause Erectile Dysfunction?

For most men, erectile function is preserved.

Current evidence does not demonstrate a major difference in erectile-function outcomes between GreenLight PVP and conventional TURP.

Sexual function, however, is influenced by many factors including age, vascular health, diabetes, medications and pre-existing erectile function.

Less Common Complications

Potential complications include:

  • Significant bleeding
  • Urinary tract infection
  • Temporary urinary retention
  • Urethral stricture
  • Bladder-neck contracture
  • Temporary urinary incontinence
  • Rare persistent urinary incontinence
  • Persistent urgency or overactive bladder symptoms
  • Incomplete removal of obstructing tissue
  • Recurrent prostate enlargement
  • Requirement for further prostate surgery

One Important Limitation: There Is Usually No Tissue for Pathology

This is an important difference between GreenLight PVP and TURP or HoLEP.

With TURP, prostate chips are removed.

With HoLEP, the enucleated adenoma is morcellated and retrieved.

With GreenLight PVP, much of the treated tissue is vaporised.

Consequently, there may be little or no prostate tissue available for histological examination.

For this reason, appropriate assessment for prostate cancer should be undertaken before GreenLight surgery when clinically indicated, using PSA, examination, MRI and/or prostate biopsy where appropriate.

GreenLight vs TURP vs HoLEP vs Robotic-Assisted Simple Prostatectomy

There is no single “best” prostate operation for every man.

The appropriate procedure depends on:

prostate size + prostate anatomy + bleeding risk + bladder function + patient priorities + surgeon expertise.

Feature GreenLight PVP TURP HoLEP Robotic Simple Prostatectomy / Enucleation
Approach Transurethral Transurethral Transurethral Abdominal robotic
Energy 532 nm laser Electrical 2,140 nm holmium laser Robotic dissection ± energy
Tissue treatment Vaporisation Resection Anatomical enucleation Anatomical enucleation
Tissue for pathology Limited/none Yes Yes Yes
Bleeding Very low Low-moderate Very low Low-moderate
Best established size ~30–80 mL ~30–80 mL Virtually size-independent Large/very large prostates
Large prostate >100 mL Possible, but less ideal Less attractive Excellent option Excellent option
Catheter duration Usually short Short Usually short Usually longer
Hospital stay Short Short Short Generally longer
Anticoagulation advantage Good Less favourable Good Less favourable
Learning curve Moderate Familiar technique Significant Significant
Durability in very large glands Less certain Good Excellent Excellent
Incisions None None None Abdominal port incisions

GreenLight vs TURP

TURP has traditionally been regarded as the benchmark operation against which newer BPH procedures are compared.

GreenLight achieves broadly similar improvements in urinary symptoms and flow for appropriately selected prostates.

Its principal advantages over TURP are:

  • Less perioperative bleeding
  • Lower transfusion requirements
  • Shorter catheterisation
  • Shorter hospitalisation
  • Excellent visibility during surgery
  • Potential advantages in patients at increased bleeding risk

Its disadvantages include:

  • Longer operating time in some patients
  • Lack of tissue for histology
  • Potentially higher retreatment rates over longer follow-up
  • Reduced efficiency as prostate size becomes very large

Long-term population data suggest that although reoperations for bleeding are less common after PVP, overall cumulative reoperation may be higher than after TURP.

So GreenLight’s strength is low perioperative morbidity, while TURP retains excellent durability and provides tissue for histology.

GreenLight vs HoLEP

HoLEP is fundamentally different.

GreenLight predominantly vaporises the obstructing prostate.

HoLEP enucleates the adenoma anatomically from the surgical capsule, rather like removing the inside of an orange while leaving the peel behind.

HoLEP uses a pulsed 2,140 nm holmium laser, which is strongly absorbed by water rather than haemoglobin.

The major advantage of HoLEP is that it is essentially prostate-size independent.

A 40 mL prostate can be enucleated.

So can a 100, 150 or even 200+ mL prostate in experienced hands.

The AUA guideline specifically recognises HoLEP as a prostate size-independent surgical option.

HoLEP also removes a larger proportion of the obstructing adenoma and provides tissue for histological examination.

Its principal disadvantages are its technical complexity, significant learning curve and potential for temporary postoperative stress urinary incontinence, particularly following treatment of very large glands.

For very large prostates, HoLEP will generally provide more complete anatomical adenoma removal than conventional GreenLight vaporisation.

GreenLight vs Robotic-Assisted Prostate Enucleation

For very large benign prostates, another option is robot-assisted simple prostatectomy (RASP), sometimes described as robotic prostate adenoma enucleation.

This is very different from a robotic radical prostatectomy performed for prostate cancer.

The entire prostate is not removed.

Instead, the enlarged benign adenoma is dissected away from the remaining prostate capsule.

It essentially achieves the same anatomical objective as HoLEP but approaches the prostate through the abdomen and bladder or prostate capsule rather than through the urethra.

Robotic simple prostatectomy is particularly attractive for very large or anatomically complex prostates, particularly when associated bladder pathology can be addressed simultaneously.

Its disadvantages include:

  • Abdominal surgery
  • Robotic port incisions
  • Longer catheterisation
  • Longer hospital stay
  • Greater surgical invasiveness
  • Higher resource utilisation

Recent comparative evidence suggests that both robotic simple prostatectomy and laser enucleation provide excellent outcomes for prostates ≥80 mL, while endoscopic laser enucleation generally provides faster perioperative recovery.

So Which Operation Is Best?

A useful way of thinking about these procedures is not as competitors, but as different tools for different prostates.

GreenLight PVP

Particularly attractive for:

  • Small-to-moderately enlarged prostates
  • Approximately 30–80 mL glands
  • Patients where minimising bleeding is particularly important
  • Older or medically complex patients
  • Patients requiring rapid recovery and short catheterisation

TURP

Remains an excellent option for:

  • Small-to-moderately enlarged prostates
  • Conventional benign prostatic obstruction
  • Situations where prostate tissue for histology is desirable
  • Centres with extensive TURP experience

HoLEP

Particularly attractive for:

  • Moderate, large and extremely large prostates
  • Men requiring maximal adenoma removal
  • Recurrent BPH after previous surgery
  • Patients where long-term durability is particularly important
  • Patients wishing to avoid abdominal surgery despite a very large prostate

Robotic-Assisted Simple Prostatectomy

Particularly attractive for:

  • Very large prostates
  • Complex prostate anatomy
  • Large intravesical adenomas
  • Patients with associated bladder pathology requiring treatment
  • Situations where endoscopic enucleation expertise is unavailable or a robotic approach offers anatomical advantages

The Bottom Line

GreenLight laser photoselective vaporisation is an effective, minimally invasive surgical treatment for benign prostate enlargement.

Its 532 nm laser is selectively absorbed by haemoglobin, allowing prostate tissue to be vaporised while simultaneously achieving excellent haemostasis.

Its particular strengths are:

less bleeding, short catheterisation, short hospitalisation and rapid recovery.

For appropriately selected men with moderate-sized prostates, symptom improvement is broadly comparable with TURP.

As prostate size increases, however, anatomical enucleation becomes increasingly attractive. HoLEP and robotic-assisted simple prostatectomy remove the adenoma more completely and are particularly effective for very large prostates. HoLEP achieves this endoscopically, whereas robotic surgery achieves it through an abdominal approach.

The choice therefore should not simply be:

“Which operation is newest?”

A better question is:

“Which operation best suits this prostate, this bladder and this patient?”

Prostate size and shape, urinary symptoms, bladder function, bleeding risk, medications, general health, PSA assessment, sexual priorities and the surgeon’s experience should all contribute to the final decision.

This information is intended for general patient education and does not replace individual assessment and discussion with a urologist.

 

Urethral Caruncle: A Small Lump That Can Cause Big Concern

/0 Comments/in , /by

Finding a red or fleshy lump around the opening of the urethra can understandably be alarming. Fortunately, one of the most common causes, particularly in women after menopause, is a urethral caruncle.

A urethral caruncle is usually benign (non-cancerous) and may cause no problems at all. However, because several other conditions can look similar, a new, enlarging, bleeding or unusual urethral lesion deserves proper assessment.

What is a urethral caruncle?

A urethral caruncle is a small, fleshy growth arising from the lining of the urethral opening, or urethral meatus.

It typically appears as a soft red, pink or sometimes darker-red polypoid lesion at the edge of the urethral opening. It most commonly arises from the posterior or lower margin of the urethral meatus.

Caruncles occur predominantly in postmenopausal women, although they can occasionally occur in younger women.

Importantly, a urethral caruncle is not considered a precancerous condition. Its significance lies mainly in the symptoms it can produce and the fact that other urethral conditions can occasionally imitate its appearance.

What causes a urethral caruncle?

The exact cause is not completely understood, but several factors are thought to contribute.

Reduced oestrogen after menopause

This is probably the most important association.

After menopause, falling oestrogen levels cause thinning and reduced elasticity of the tissues surrounding the vagina and urethra. This is part of what is now commonly called genitourinary syndrome of menopause (GSM).

The urethral lining may become more fragile and susceptible to irritation, inflammation and prolapse.

Chronic inflammation and irritation

Repeated local irritation may contribute to inflammation around the urethral opening and subsequent formation of a caruncle.

Urethral mucosal prolapse

A caruncle may represent a localised form of prolapse of the urethral lining. This helps explain why the lesion usually occurs at the edge of the urethral opening.

What does a urethral caruncle look like?

A typical caruncle is:

  • Small and fleshy
  • Red or pink
  • Soft
  • Usually located along the lower edge of the urethral opening
  • Occasionally friable, meaning that it bleeds easily when touched
  • Sometimes tender or inflamed

They vary considerably in size. Some are barely noticeable, while larger lesions may protrude sufficiently to be felt or seen by the patient.

Although the appearance may be quite characteristic, appearance alone should not always be relied upon when a lesion is atypical.

What symptoms can it cause?

Many urethral caruncles are discovered incidentally during a pelvic examination and cause absolutely no symptoms.

When symptoms do occur, they may include:

Bleeding

The surface of a caruncle can be delicate and vascular. Patients may notice:

  • Spotting on underwear
  • Blood after wiping
  • Bleeding after intercourse
  • Blood noticed after passing urine

One important distinction is determining whether the blood is actually coming from the urethral lesion or whether there is true blood within the urine (haematuria).

Persistent haematuria may require additional investigation.

Pain or tenderness

An inflamed caruncle can become uncomfortable, particularly with wiping, intercourse or local pressure.

Burning when passing urine

Some patients experience dysuria or a stinging sensation as urine passes across the inflamed tissue.

A visible or palpable lump

Some women first become aware of the condition because they see or feel a small lump at the urethral opening.

Urinary symptoms

Large caruncles only rarely interfere significantly with urinary flow. If there is difficulty passing urine, a weak stream or urinary retention, other causes should also be considered.

How is a urethral caruncle diagnosed?

Diagnosis usually begins with a careful examination of the urethral opening and surrounding genital tissues.

A typical small caruncle in a postmenopausal woman often has a characteristic appearance.

Your doctor may also assess for associated vaginal and urethral atrophy and ask about urinary symptoms, recurrent urinary infections, bleeding and haematuria.

Depending on the circumstances, investigations may include:

  • Urinalysis
  • Urine culture if infection is suspected
  • Assessment for haematuria
  • Cystoscopy if there are unexplained urinary symptoms or blood in the urine
  • Biopsy or removal of the lesion when its appearance is atypical

Does a urethral caruncle need treatment?

Not necessarily.

A small, typical caruncle that causes no symptoms may simply be observed.

Treatment is generally considered when the lesion causes bleeding, pain, irritation or bothersome urinary symptoms, or when there is uncertainty about the diagnosis.

1. Observation

If the lesion is small, has a typical appearance and causes no symptoms, reassurance and observation may be all that is required.

This avoids treating something that is essentially harmless.

2. Topical vaginal oestrogen

In postmenopausal women, topical oestrogen therapy is frequently used, particularly when there are accompanying features of genitourinary syndrome of menopause.

Oestrogen can improve the quality and thickness of the tissues around the urethra and vagina and may allow a small caruncle to shrink considerably or resolve.

Treatment usually requires several weeks rather than several days.

The suitability of vaginal oestrogen should be discussed with your doctor, particularly if you have a history of an oestrogen-sensitive malignancy or another reason to avoid hormonal therapy.

3. Anti-inflammatory and supportive treatment

Where local inflammation is prominent, conservative measures may occasionally include:

  • Avoidance of irritating soaps and products
  • Treatment of associated infection if present
  • Appropriate topical therapy
  • Simple analgesia when required

These treatments may improve symptoms but do not necessarily remove the lesion itself.

When is surgery required?

Surgical removal may be recommended when the caruncle is:

  • Persistently painful
  • Repeatedly bleeding
  • Large or bothersome
  • Not responding to conservative treatment
  • Increasing in size
  • Firm, irregular, ulcerated or otherwise atypical
  • Associated with uncertainty about the diagnosis

Surgery usually involves excision of the lesion at its base, often as a relatively minor procedure.

The removed tissue can then be sent to a pathologist for examination under the microscope.

Possible complications are uncommon but can include bleeding, infection, discomfort, recurrence and, rarely, scarring or narrowing of the urethral opening.

Can a urethral caruncle be cancerous?

A true urethral caruncle is benign.

The more important question is whether a lesion that looks like a caruncle could occasionally be something else.

Several conditions may resemble a caruncle, including:

  • Urethral mucosal prolapse
  • Urethral polyps
  • Periurethral cysts
  • Urethral diverticulum
  • Genital warts
  • Inflammatory lesions
  • Melanoma
  • Urethral carcinoma
  • Other uncommon benign or malignant tumours

Cancer masquerading as an apparently innocent urethral lesion is uncommon, but this is precisely why an atypical lesion should not simply be labelled a caruncle and forgotten.

When should a biopsy be considered?

Biopsy or complete excision is particularly worth considering when a lesion is:

  • Irregular or unusually firm
  • Ulcerated
  • Pigmented
  • Rapidly enlarging
  • Persistently bleeding
  • Unusually large
  • Not responding as expected to conservative treatment
  • Associated with enlarged groin lymph nodes
  • Clinically inconsistent with a typical caruncle

In medicine, sometimes the smallest lump deserves a second look rather than a dramatic name.

Urethral caruncle versus urethral prolapse

These conditions can look similar but are not quite the same.

A urethral caruncle generally involves only a portion of the circumference of the urethral opening, most commonly its posterior margin.

A urethral prolapse usually involves the entire circumference of the urethral lining, creating a circular or doughnut-shaped ring of tissue surrounding the opening.

The distinction can influence management.

What about blood in the urine?

This is particularly important.

A caruncle may bleed externally and make it appear that blood has come from the urine. However, visible haematuria should not automatically be attributed to a urethral caruncle.

Depending on age, symptoms and individual risk factors, haematuria may require investigation of the bladder, kidneys and urinary tract.

The presence of a convenient little red lump should therefore not distract from investigating genuine haematuria appropriately.

Will a urethral caruncle come back?

Recurrence after treatment is possible, particularly if the underlying postmenopausal tissue changes persist.

Treatment of associated genitourinary syndrome of menopause may therefore remain useful even after the immediate caruncle has improved or been removed.

When should you see a urologist?

Consider seeking medical assessment if you notice:

  • A new lump around the urethral opening
  • Persistent urethral pain
  • Recurrent bleeding
  • Blood in the urine
  • A lesion that is enlarging
  • Difficulty passing urine
  • Recurrent urinary infections
  • A lesion that does not improve with treatment

Most urethral caruncles turn out to be harmless, but examination provides reassurance and ensures that less common conditions are not overlooked.

The Bottom Line

A urethral caruncle is a common benign lesion of the urethral opening, seen particularly in postmenopausal women.

Many require no treatment at all. When symptoms occur, topical vaginal oestrogen and conservative measures are often appropriate first-line options. Persistent, troublesome or atypical lesions may require surgical excision and pathological examination.

The most important message is simple: a typical urethral caruncle is usually nothing to fear, but an unusual urethral lesion deserves proper assessment rather than assumption.

Patient information disclaimer

This information is intended for general education and should not replace individual medical advice. A urethral or vulval lump, unexplained bleeding or blood in the urine should be assessed by an appropriately qualified healthcare professional.

Intravesical Drugs for Non-Muscle-Invasive Bladder Cancer

/0 Comments/in , /by

Treating the tumour and reducing the risk of it coming back

Bladder cancer has an inconvenient habit: even after a visible tumour has been completely removed, new tumours can sometimes return elsewhere in the bladder.

For selected patients with non-muscle-invasive bladder cancer (NMIBC), previously often called superficial bladder cancer, Mitomycin C can be placed directly into the bladder to destroy residual cancer cells and reduce the chance of recurrence. It is one of the therapies available. It will be discussed on its own.

This treatment is called intravesical Mitomycin C.

The advantage of intravesical treatment is rather elegant: instead of sending chemotherapy around the entire body, the medication is delivered directly to the bladder lining where it is needed.

What is Mitomycin C?

Mitomycin C is an anti-cancer chemotherapy medication originally derived from Streptomyces bacteria.

When used for bladder cancer, the medication is usually introduced directly into the bladder through a urinary catheter rather than being given intravenously.

This allows a relatively high concentration of chemotherapy to come into direct contact with the urothelium while limiting systemic exposure.

Intravesical Mitomycin is used particularly following transurethral resection of bladder tumour (TURBT) and in selected patients requiring an induction course of intravesical chemotherapy.

Why is Mitomycin C used?

The first and most important treatment for most visible non-muscle-invasive bladder tumours is a TURBT.

During TURBT, the visible tumour is removed and tissue is sent to pathology to determine:

  • tumour type
  • tumour grade
  • depth of invasion
  • presence or absence of carcinoma in situ (CIS)
  • whether muscle is present in the specimen
  • whether cancer has invaded the bladder muscle.

The pathology results allow the tumour to be classified into a recurrence and progression risk category.

Mitomycin C may then be recommended to reduce the risk of tumour recurrence.

When is Mitomycin C used?

There are several different situations in which intravesical Mitomycin C may be considered.

1. A single dose immediately after TURBT

In appropriately selected patients, a single dose of intravesical chemotherapy can be given following TURBT.

Australian eviQ guidance describes administration within 24 hours and preferably within six hours of TURBT. AUA guidance similarly recommends considering a single postoperative instillation within 24 hours for suspected or known low- or intermediate-risk disease.

The purpose is to destroy:

  • microscopic tumour cells remaining after resection
  • free-floating tumour cells released during surgery
  • tumour cells that might otherwise implant elsewhere on the bladder lining.

Think of TURBT as removing the weeds you can see, while the immediate intravesical treatment targets some of the microscopic seeds left behind.

Importantly, a single postoperative instillation primarily reduces recurrence. It has not been shown to provide the same benefit for progression or survival.

2. Induction Mitomycin C

Some patients with intermediate-risk NMIBC may benefit from a course of intravesical chemotherapy rather than a single treatment.

A commonly used regimen is:

Mitomycin C once weekly for six weeks.

Australian eviQ protocols include a six-week induction course for appropriate patients with Ta, T1 or CIS-containing urothelial carcinoma classified as intermediate risk, as an alternative to BCG in selected circumstances.

The exact treatment schedule should be individualised according to:

  • tumour grade
  • pathological stage
  • tumour size
  • number of tumours
  • previous recurrence rate
  • previous intravesical therapy
  • presence of CIS
  • tolerance of treatment
  • overall risk of progression.

What about aggressive superficial bladder cancer?

The term “superficial bladder cancer” can be misleading.

A cancer can remain confined to the bladder lining or lamina propria and still behave aggressively.

Higher-risk features include:

  • high-grade urothelial carcinoma
  • T1 disease
  • carcinoma in situ
  • multiple tumours
  • large tumours
  • frequently recurrent disease
  • certain adverse pathological features.

For genuinely high-risk NMIBC, particularly high-grade T1 disease and CIS, intravesical BCG immunotherapy generally has a central role when bladder preservation is appropriate.

Mitomycin C should therefore not automatically be regarded as a substitute for BCG in every patient with aggressive NMIBC.

Treatment needs to be based on the patient’s pathological risk group and previous response to therapy.

In selected circumstances, Mitomycin may nevertheless be considered, including when BCG is unsuitable, poorly tolerated, unavailable or as part of specific sequential intravesical treatment protocols.

Patients with very-high-risk disease also require discussion about whether bladder-preserving intravesical treatment remains appropriate or whether radical cystectomy should be considered.

How does Mitomycin C work?

Mitomycin C is an alkylating anti-tumour agent.

After entering a cancer cell, the drug is activated and produces reactive metabolites that bind to DNA.

It causes cross-linking of DNA strands, preventing the DNA from separating normally.

As a result, the cancer cell has difficulty:

  • replicating its DNA
  • dividing
  • repairing damaged DNA
  • continuing normal cellular function.

Ultimately, susceptible tumour cells die.

Because Mitomycin is placed directly into the bladder, it can attack residual malignant cells while generally producing much less systemic exposure than intravenous chemotherapy.

What happens during treatment?

Intravesical treatment is usually performed as an outpatient procedure.

A small urinary catheter is passed through the urethra into the bladder.

The bladder is emptied completely and the Mitomycin solution is then introduced through the catheter.

The catheter may then be removed or temporarily clamped, depending upon the treatment protocol.

The medication is usually retained within the bladder for approximately one to two hours.

Patients are generally advised to restrict fluids beforehand so that the medication is not excessively diluted. Australian eviQ protocols advise restricting fluids for approximately four to six hours before and during treatment, with appropriate adjustment of diuretic medication where relevant.

After the prescribed treatment period, the medication is passed out with the urine or drained through the catheter.

Side effects of intravesical Mitomycin C

Most patients tolerate treatment reasonably well because relatively little of the medication is normally absorbed into the bloodstream.

The commonest problems involve irritation of the bladder.

Chemical cystitis

Mitomycin can irritate the bladder lining and cause:

  • burning when passing urine
  • urinary frequency
  • urgency
  • bladder discomfort
  • pelvic discomfort
  • mild haematuria.

These symptoms frequently develop within hours of treatment and usually settle over the following few days.

Urinary tract infection

A urinary infection can occasionally occur following catheterisation.

Symptoms may include:

  • increasing dysuria
  • cloudy or offensive urine
  • fever
  • chills
  • worsening urinary frequency
  • feeling generally unwell.

A urine culture may be required if infection is suspected.

Skin irritation

Mitomycin is a cytotoxic medication and contact with the skin should be avoided.

Urine containing residual medication may irritate the skin around the urethra or genital area.

Patients should therefore follow the specific hygiene and toilet precautions provided by their treating unit.

Allergic reaction

Hypersensitivity reactions are uncommon but possible.

Symptoms can include:

  • skin rash
  • itching
  • facial redness
  • wheezing
  • breathlessness
  • dizziness
  • fever or chills.

Severe allergic reactions are rare but require urgent medical attention.

Less common but important complications

Although uncommon, Mitomycin can occasionally produce significant complications.

Severe chemical cystitis

Repeated bladder irritation can occasionally become severe.

Persistent inflammation may lead to:

  • chronic bladder pain
  • reduced bladder capacity
  • bladder fibrosis
  • rarely, bladder contraction.

Patients who already have a small-capacity bladder require particular caution because of the potential risk of further bladder contraction.

Extravasation

One of the most important complications is Mitomycin extravasation.

This means that Mitomycin escapes through an injured or perforated bladder wall into the surrounding tissues.

Although rare, this can produce significant tissue injury.

Reported complications include:

  • severe pelvic inflammation
  • tissue necrosis
  • abscess formation
  • bladder injury
  • fistula formation
  • damage to surrounding genital tissues.

Symptoms can occur immediately, but importantly they may also appear weeks or even months after treatment. Persistent or unexplained pelvic or abdominal pain following intravesical Mitomycin therefore deserves investigation.

An important precaution after TURBT

Intravesical Mitomycin should not simply be administered automatically following every TURBT.

If there is any suspicion that the bladder has been perforated, the medication should not be given.

AUA guidance advises against postoperative intravesical chemotherapy following a suspected perforation or extensive resection. Australian eviQ guidance similarly excludes postoperative Mitomycin when bladder perforation has occurred.

This is important because chemotherapy escaping through a bladder perforation can cause substantial tissue injury.

When should Mitomycin treatment be postponed?

Intravesical Mitomycin is generally avoided or postponed in the presence of:

  • visible haematuria
  • confirmed urinary tract infection
  • traumatic catheterisation
  • fever or unexplained febrile illness
  • known allergy to Mitomycin
  • suspected or confirmed bladder perforation
  • significant bladder injury following surgery.

Australian protocols specifically advise against treatment following traumatic catheterisation, with visible haematuria, active UTI or recent bladder injury.

If catheterisation is traumatic or produces bleeding on the day of treatment, the treatment is usually deferred.

Does Mitomycin cause the usual chemotherapy side effects?

Usually not.

Because the medication is placed into the bladder rather than routinely given intravenously, systemic absorption is generally very low.

Therefore classic chemotherapy problems such as:

  • hair loss
  • severe nausea
  • widespread immunosuppression
  • profound fatigue
  • bone marrow suppression

are unusual with standard intravesical therapy.

Systemic absorption can occur rarely, however, particularly when the bladder lining has been significantly disrupted. Myelosuppression is considered a potential but uncommon complication, and a full blood count may be appropriate if a patient becomes unexpectedly systemically unwell.

Precautions after treatment

Mitomycin remains a cytotoxic chemotherapy drug, even when delivered directly into the bladder.

Patients should therefore follow their treating unit’s instructions carefully regarding:

  • toilet hygiene
  • handling urine
  • washing contaminated skin
  • hand washing
  • fluid intake following treatment
  • management of contaminated clothing.

Patients should also tell their treating team about all medications they are taking and whether they are receiving antibiotics, diuretics or other cancer treatments.

When should you seek urgent medical advice?

Contact your treating team promptly if you develop persistent or worsening urinary symptoms after treatment.

More urgent assessment is required for symptoms such as:

  • temperature of 38°C or higher
  • inability to pass urine
  • significant or persistent haematuria
  • severe pelvic or abdominal pain
  • chills or shaking
  • shortness of breath
  • severe rash or suspected allergic reaction
  • persistent symptoms that are worsening rather than settling.

Severe pelvic or abdominal pain following intravesical Mitomycin is particularly important because, although uncommon, it may indicate bladder injury or extravasation.

Mitomycin does not replace surveillance

One of the most important points about NMIBC is that successful treatment does not mean surveillance can stop.

Even after apparently complete removal and intravesical chemotherapy, urothelial tumours can recur.

Depending upon the original tumour’s risk category, ongoing surveillance may include:

  • flexible cystoscopy
  • urine cytology
  • repeat TURBT
  • upper urinary tract imaging
  • further intravesical treatment.

Patients with higher-risk disease require considerably closer surveillance than those with a solitary low-grade tumour.

Mitomycin C versus BCG

These treatments are sometimes discussed together, but they work differently.

Mitomycin C is chemotherapy. It directly damages the DNA of susceptible tumour cells.

BCG is immunotherapy. It stimulates a local immune response within the bladder that attacks urothelial cancer cells.

The appropriate treatment depends upon the biological behaviour and risk category of the tumour.

For some patients, Mitomycin provides an effective and relatively well-tolerated strategy for reducing recurrence. For patients with higher-risk disease, BCG or more aggressive treatment may be preferable.

The important question is therefore not simply:

“Mitomycin or BCG?”

It is:

“What is the risk of this particular bladder cancer recurring or progressing, and which treatment provides the safest and most effective way of reducing that risk?”

The Bottom Line

Intravesical Mitomycin C is an established treatment for selected patients with non-muscle-invasive urothelial carcinoma of the bladder.

It may be used as a single treatment immediately following TURBT or as a course of intravesical chemotherapy in appropriately selected patients.

By placing chemotherapy directly into the bladder, Mitomycin can destroy residual cancer cells and reduce tumour recurrence while limiting exposure of the rest of the body.

Most side effects are related to temporary bladder irritation. Serious complications such as bladder injury, extravasation, fibrosis and tissue necrosis are uncommon but important, which is why careful patient selection and attention to precautions are essential.

And perhaps the most important message: Mitomycin reduces risk. It does not make follow-up optional.

Bladder cancer has a reputation for making return appearances, so regular cystoscopic surveillance remains an essential part of treatment.

This information is intended for general education and should not replace individual medical advice. Treatment of non-muscle-invasive bladder cancer should be tailored to the tumour’s stage, grade and recurrence/progression risk, previous treatments and the individual patient’s circumstances.

Intravesical Therapy for High-Risk Bladder Cancer

/0 Comments/in , /by

BCG treatment, what is it?

BCG, short for Bacillus Calmette–Guérin, is one of the most effective treatments available for high-risk non-muscle-invasive bladder cancer (NMIBC).

BCG is best known as a vaccine originally developed against tuberculosis. In bladder cancer, however, it is used in a very different way. Rather than being injected as a vaccination, a solution containing BCG is placed directly into the bladder through a fine urinary catheter.

BCG is not conventional chemotherapy. It is a form of local immunotherapy. Its purpose is to stimulate the body’s immune system inside the bladder so that immune cells recognise and attack remaining bladder cancer cells.

For appropriately selected patients, BCG can significantly reduce the risk of bladder cancer returning and, importantly, reduce the risk of progression to more invasive disease.

Which bladder cancers are treated with BCG?

BCG is primarily used for high-risk or locally aggressive non-muscle-invasive urothelial carcinoma following adequate transurethral resection of the bladder tumour (TURBT).

Typical indications include:

  • Carcinoma in situ (CIS or Tis)
  • High-grade Ta urothelial carcinoma, particularly when large, multifocal or recurrent
  • High-grade T1 urothelial carcinoma
  • Recurrent high-grade non-muscle-invasive bladder cancer
  • Selected patients with multiple adverse pathological features
  • Selected patients with urothelial CIS involving the prostatic urethra as part of a bladder-preserving strategy

Current international guidelines recommend a six-week induction course of BCG for high-risk NMIBC, followed by maintenance treatment in patients who respond.

BCG is generally not required for a solitary low-risk, low-grade Ta bladder tumour. These cancers have a different biological behaviour and are usually managed with TURBT, sometimes combined with immediate intravesical chemotherapy and subsequent surveillance.

Why is BCG particularly important for carcinoma in situ?

Carcinoma in situ (CIS) deserves special attention.

Unlike the familiar papillary bladder tumour that projects into the bladder cavity, CIS can appear as a relatively flat, red or velvety abnormality of the bladder lining. Despite looking less dramatic, it is biologically aggressive.

CIS has a significant risk of recurrence and progression to muscle-invasive bladder cancer if inadequately treated. It cannot simply be “scraped away” by TURBT and forgotten.

For this reason, CIS generally requires either:

BCG immunotherapy
or, in selected very-high-risk circumstances,
radical cystectomy.

BCG produces substantially better response rates for CIS than intravesical chemotherapy in appropriate patients and has been shown to reduce the risk of progression.

How does BCG actually work?

The mechanism is fascinating because BCG does not simply poison cancer cells in the way traditional chemotherapy does.

Think of it less as dropping a bomb on the tumour and more as turning on the bladder’s local security system.

After BCG is introduced into the bladder, organisms interact with the urothelial surface and tumour cells. This produces a strong local inflammatory and immune response.

The process includes:

BCG attachment and internalisation

BCG interacts with urothelial cells, tumour cells and immune cells within the bladder.

Activation of innate immunity

Neutrophils, macrophages, dendritic cells and other immune cells are recruited into the bladder.

Cytokine release

A complex inflammatory signalling response develops, involving multiple cytokines and chemokines.

Activation of adaptive immunity

T lymphocytes and other components of the immune system become involved in recognising and destroying malignant urothelial cells.

The end result is an intentionally stimulated immune environment that makes the bladder a considerably less comfortable neighbourhood for residual cancer cells.

Before starting BCG

Successful BCG treatment starts with adequate staging and tumour clearance.

Patients will usually have undergone TURBT with pathological assessment confirming the tumour grade and stage.

In high-grade T1 disease, a repeat or second-look TURBT is frequently recommended to ensure complete resection and exclude previously unrecognised muscle-invasive disease.

Depending upon the tumour characteristics, assessment may also include:

  • Urine cytology
  • CT urography or other upper urinary tract imaging
  • Repeat cystoscopy
  • Re-resection of the original tumour site
  • Assessment of the prostatic urethra in selected patients
  • Review of pathology where variant histology or unusual findings are present

Very-high-risk cases are increasingly appropriate for multidisciplinary discussion because some patients may benefit more from early radical cystectomy than prolonged attempts at bladder preservation.

How is BCG given?

BCG is administered as an outpatient procedure.

A small catheter is gently passed through the urethra into the bladder. After the bladder has been drained, the BCG solution is instilled through the catheter.

The catheter is then removed unless there is a particular reason for it to remain temporarily.

The BCG solution is generally retained within the bladder for approximately two hours, where tolerated.

Patients receive specific instructions regarding fluid intake before treatment and safe handling of urine afterwards because BCG contains live attenuated Mycobacterium bovis.

The standard induction course

The traditional induction course consists of:

BCG once weekly for six weeks

This remains the standard initial regimen for high-risk disease.

Importantly, attempts to substantially reduce the number of induction and maintenance instillations have resulted in inferior cancer control. The six-week induction course therefore remains an important part of established treatment.

What happens after the first six treatments?

Following induction BCG, the bladder is reassessed.

This will generally involve:

  • Cystoscopy
  • Urinary cytology
  • Biopsy or repeat TURBT if an abnormality is detected
  • Additional investigation when cytology remains suspicious despite a normal-looking bladder

The key question is simple:

Has the cancer responded?

If it has, the next step is usually maintenance BCG.

Maintenance BCG

BCG works better in high-risk bladder cancer when appropriate maintenance treatment is added rather than simply giving six doses and stopping.

A widely used maintenance schedule consists of:

Induction

Once weekly × 6 weeks

followed by:

Maintenance

Once weekly × 3 weeks at:

  • 3 months
  • 6 months
  • 12 months
  • 18 months
  • 24 months
  • 30 months
  • 36 months

This is often referred to as a SWOG-style maintenance schedule.

Current European guidance recommends full-dose BCG for one to three years in high-risk disease, with the benefit of years two and three balanced against toxicity, patient tolerance and BCG availability. Three years of maintenance provides additional protection against recurrence in high-risk patients compared with one year.

Not every patient will receive every planned dose. Treatment may need to be delayed, reduced or discontinued because of side effects, infection, BCG availability or changes in the cancer.

When should BCG NOT be given?

Because BCG contains live attenuated bacteria, certain precautions are essential.

BCG should not be administered:

  • Within the first two weeks after TURBT
  • When there is visible haematuria
  • Following traumatic catheterisation
  • In the presence of a symptomatic urinary tract infection

Treatment should instead be delayed until it can be administered safely.

Additional caution is required in significantly immunocompromised patients, and individual circumstances should be discussed with the treating urologist.

Common side effects of BCG

BCG deliberately produces inflammation within the bladder, so some urinary symptoms are expected.

The most common side effects include:

Urinary frequency and urgency

Patients may feel the need to urinate frequently or suddenly.

Burning during urination

Mild-to-moderate dysuria is common for a day or two following treatment.

Blood in the urine

A small amount of haematuria can occur.

Bladder discomfort

Some patients describe suprapubic discomfort, cramping or a sensation resembling cystitis.

Flu-like symptoms

Fatigue, muscle aches, chills and a low-grade temperature can occur as the immune system responds to treatment.

These symptoms usually settle within approximately 24–48 hours.

The bladder may complain rather loudly about BCG, but mild short-lived irritation is usually part of the intended inflammatory response rather than evidence that something has gone wrong.

When should you contact your urologist?

Patients should contact their treating team if symptoms are unusually severe or fail to settle.

Particular attention should be paid to:

  • Persistent fever
  • High fever or rigors
  • Severe urinary symptoms
  • Inability to pass urine
  • Persistent or heavy haematuria
  • Significant deterioration in general wellbeing
  • Symptoms continuing substantially longer than expected

Persistent fever after BCG deserves particular attention.

Serious complications of BCG

Serious complications are uncommon, but they are important because BCG contains viable attenuated bacteria.

Potential complications include:

Severe BCG cystitis

Persistent bladder inflammation may occasionally become sufficiently troublesome that treatment needs to be delayed or discontinued.

Granulomatous prostatitis

BCG can produce an inflammatory reaction within the prostate. This can occasionally produce an abnormal prostate examination or elevated PSA and may mimic prostate cancer clinically.

Epididymo-orchitis

Rarely, BCG-related inflammation or infection can involve the epididymis or testis.

Upper urinary tract involvement

Granulomatous infection of the kidney is uncommon but recognised.

BCG infection

Localised or systemic infection with Mycobacterium bovis can occur.

BCG sepsis

This is a rare but potentially life-threatening complication.

A patient who becomes systemically unwell with persistent high fever, rigors, hypotension, respiratory symptoms or other features of sepsis following BCG requires urgent medical assessment.

Treatment may require hospital admission, infectious diseases involvement, anti-mycobacterial therapy and other supportive treatment.

BCG should therefore be respected. It is an extraordinarily useful treatment, but it is not simply another bladder wash.

What if BCG is poorly tolerated?

Treatment does not always have to proceed according to the calendar regardless of symptoms.

Depending upon severity, management can include:

  • Postponing the next instillation
  • Symptomatic treatment
  • Investigation for bacterial urinary infection
  • Assessment for BCG-related infection
  • Dose modification in selected circumstances
  • Discontinuation of BCG when toxicity becomes unacceptable

Persistent significant symptoms should be assessed rather than repeatedly giving further BCG and hoping the bladder eventually stops protesting.

What if the cancer returns after BCG?

This is one of the most important aspects of BCG treatment.

Not every recurrence after BCG means the same thing. The timing, pathology and amount of previous BCG exposure all matter.

Terms such as:

  • BCG-exposed
  • BCG-relapsing
  • BCG-refractory
  • BCG-unresponsive

describe different clinical situations.

Of these, BCG-unresponsive disease is particularly important because these tumours are unlikely to benefit from simply giving more BCG.

Current guidelines recommend radical cystectomy as the oncologically preferred treatment for appropriate patients with BCG-unresponsive high-grade disease.

When should radical cystectomy be considered?

BCG is intended to preserve the bladder, but preserving the bladder should never become more important than controlling the cancer.

Early radical cystectomy should be discussed in patients with very-high-risk features such as:

  • Persistent high-grade T1 disease
  • Recurrent high-grade disease despite adequate BCG
  • BCG-unresponsive disease
  • T1 disease associated with CIS
  • Certain variant histologies
  • Lymphovascular invasion
  • Extensive or multifocal high-grade disease
  • Other features suggesting a particularly high risk of progression

For very-high-risk NMIBC, current EAU guidance recommends discussing radical cystectomy upfront. BCG for one to three years remains an option for appropriately selected patients, particularly those who decline cystectomy or are medically unsuitable for major surgery.

Delaying cystectomy in a biologically aggressive tumour that is clearly failing BCG may compromise cancer outcomes.

Are there alternatives when BCG fails?

For patients with BCG-unresponsive disease who are unable or unwilling to undergo radical cystectomy, bladder-preserving alternatives are evolving rapidly.

Depending upon availability, tumour characteristics and local regulatory approval, options may include:

  • Sequential intravesical gemcitabine/docetaxel
  • Other intravesical chemotherapy combinations
  • Novel intravesical therapies
  • Systemic immunotherapy for selected CIS
  • Gene-based intravesical therapy in jurisdictions where available
  • Device-assisted intravesical therapy
  • Clinical trials

These treatments should not automatically be considered equivalent substitutes for radical cystectomy in a surgically fit patient with genuinely BCG-unresponsive aggressive disease. The risk of progression needs to remain at the centre of the decision.

Surveillance after BCG

BCG treatment does not eliminate the need for careful surveillance.

High-risk bladder cancer requires long-term follow-up because recurrence can occur even after an excellent initial response.

Follow-up generally involves:

Cystoscopy + urine cytology

initially at approximately 3 months, with subsequent surveillance determined by tumour risk and previous findings.

High-risk patients typically undergo frequent cystoscopy during the first two years, with gradually increasing intervals thereafter if they remain disease-free.

Periodic upper urinary tract imaging is also appropriate because high-risk urothelial carcinoma can occasionally develop within the ureters or kidneys.

Surveillance is usually long term and, for high-risk disease, often lifelong.

A practical BCG pathway

A typical pathway for high-risk non-muscle-invasive urothelial carcinoma is:

TURBT

↓

Histological confirmation of high-risk NMIBC

↓

Repeat TURBT when indicated, particularly high-grade T1 disease

↓

BCG induction: weekly × 6

↓

Cystoscopy + cytology and assessment of response

↓

If responding:

Maintenance BCG

3 weekly treatments at 3, 6 and 12 months, with continued maintenance to as long as 36 months in appropriate high-risk patients.

↓

Long-term cystoscopic surveillance

If persistent or recurrent high-grade disease:

Re-stage the bladder and determine whether the tumour represents BCG-unresponsive disease.

↓

Discuss radical cystectomy versus carefully selected bladder-preserving alternatives/clinical trials where appropriate.

The bottom line

Intravesical BCG remains a cornerstone of treatment for high-risk non-muscle-invasive urothelial carcinoma of the bladder.

Its strength lies in stimulating a powerful local immune response that reduces recurrence and helps prevent progression of aggressive superficial bladder cancer.

The usual treatment begins with six weekly instillations, followed by maintenance therapy for appropriately responding high-risk patients.

But BCG is not appropriate for every bladder tumour, and it should not be continued indefinitely when aggressive cancer is clearly failing treatment.

The most important principle is therefore not simply:

“Can we preserve the bladder?”

It is:

“Can we preserve the bladder safely without compromising cancer control?”

For patients with very-high-risk or BCG-unresponsive disease, timely discussion of radical cystectomy can be every bit as important as the BCG treatment itself.

This information is intended as general patient education and does not replace individual assessment by a urologist. BCG protocols, product availability and management of BCG-resistant disease may vary between patients and treatment centres.

Superficial Urothelial Carcinoma of the Bladder

/0 Comments/in , /by

Understanding non-muscle-invasive bladder cancer, TURBT, intravesical therapy and long-term surveillance

Being told that you have a bladder tumour is understandably alarming. The reassuring part is that many bladder cancers are discovered while they are still confined to the inner layers of the bladder and have not invaded the bladder muscle.

This is called non-muscle-invasive bladder cancer (NMIBC), historically referred to as superficial bladder cancer. NMIBC includes Ta tumours, T1 tumours and carcinoma in situ (CIS). These tumours behave very differently depending on their stage, grade and other pathological features, so treatment is tailored according to the risk of the cancer coming back (recurrence) or becoming more aggressive (progression).

The good news is that most NMIBC can initially be treated through the urethra without making an incision in the abdomen. The less convenient news is that bladder cancer has a habit of returning, which is why careful surveillance becomes an important part of treatment.

What is urothelial carcinoma?

The inside of the bladder is lined by specialised cells called urothelial cells. Cancer arising from these cells is known as urothelial carcinoma.

Urothelial carcinoma can develop anywhere along the urinary tract, including the:

  • renal collecting system
  • ureters
  • bladder
  • urethra

The bladder is by far the most common site.

When a bladder tumour has not invaded the muscular wall of the bladder, it is classified as non-muscle-invasive bladder cancer.

https://images.openai.com/static-rsc-4/y3Nkc3nnwnLWbduLwtOBo9wlGDPYvlRZ3hqmZmerWsmC4HUjhpIEvsXgWPs9IwZOQ9PLgJllQH1edLQmAni1U_538dO2IEbu48myP0AM4El4gyVQqzEuJjxyZdTq2Ak6qThyv190dh_MhP59fXKNJByHY8EL-AhSnzHK3LUJq2tbc5vhmHhLL8WBeJitn-Wb?purpose=fullsize

What causes bladder cancer?

There is rarely one identifiable cause. Instead, bladder cancer develops following genetic changes within urothelial cells, often influenced by environmental exposures over many years.

Smoking

Cigarette smoking is the most important preventable risk factor for bladder cancer.

Chemicals absorbed through cigarette smoke enter the bloodstream, are filtered by the kidneys and eventually become concentrated in the urine. The bladder lining is therefore repeatedly exposed to these carcinogens.

Stopping smoking after a bladder cancer diagnosis is strongly encouraged.

Other risk factors

These include:

  • increasing age
  • occupational exposure to certain industrial chemicals
  • previous pelvic radiotherapy
  • previous treatment with cyclophosphamide
  • chronic urinary tract irritation in selected circumstances
  • a personal history of urothelial carcinoma

Sometimes there is no obvious risk factor at all.

How does bladder cancer present?

Blood in the urine

The classic presentation is haematuria, or blood in the urine.

This may be:

Visible haematuria

The urine may suddenly become:

  • pink
  • red
  • burgundy
  • tea-coloured
  • or contain blood clots

Importantly, bleeding from a bladder tumour is frequently painless and intermittent.

The bleeding may disappear completely for days, weeks or even months. Its disappearance does not necessarily mean that the underlying problem has resolved.

Unexplained visible haematuria should always be investigated.

Microscopic haematuria

Sometimes blood is detected only on urine testing and cannot be seen with the naked eye.

Other possible symptoms

Some patients, particularly those with carcinoma in situ (CIS), may experience bladder irritation rather than obvious bleeding.

Symptoms can include:

  • urinary frequency
  • urgency
  • burning when passing urine
  • nocturia
  • pelvic or bladder discomfort
  • recurrent symptoms resembling a urinary tract infection

Persistent urinary symptoms with repeatedly negative urine cultures may therefore warrant further investigation.

Investigating suspected bladder cancer

The investigation usually involves a combination of urine testing, imaging and direct examination of the bladder.

Urine testing

A urine sample may be checked for:

  • blood
  • infection
  • inflammatory cells
  • abnormal malignant cells

Urine cytology

Urine cytology examines cells shed from the urinary tract under a microscope.

It is particularly useful for detecting high-grade urothelial carcinoma and CIS, but is considerably less sensitive for low-grade tumours.

A negative cytology therefore does not exclude bladder cancer.

Imaging the urinary tract

Patients with haematuria may require imaging of the kidneys, ureters and bladder.

Depending on the clinical circumstances, this may include:

  • renal tract ultrasound
  • CT urinary tract imaging
  • CT urography

CT urography is particularly useful when investigating haematuria because urothelial carcinoma can occasionally arise within the renal collecting system or ureters as well as the bladder.

Cystoscopy

A cystoscopy allows the urologist to look directly inside the bladder.

A thin flexible telescope is passed through the urethra, usually under local anaesthetic.

Most bladder tumours have a characteristic appearance. They may resemble delicate fronds, seaweed or a tiny underwater cauliflower attached to the bladder wall.

Flat lesions such as CIS can be much more difficult to see.

If a suspicious lesion is identified, the next step is usually a transurethral resection of bladder tumour (TURBT).

TURBT: biopsy and removal of the bladder tumour

TURBT stands for:

Transurethral Resection of Bladder Tumour

This procedure serves two important purposes:

  1. Treatment: removing all visible tumour where possible.
  2. Diagnosis and staging: providing tissue for the pathologist to determine exactly what type of tumour is present and how deeply it has invaded.

The procedure is usually performed under general or spinal anaesthesia.

A telescope called a resectoscope is passed through the urethra into the bladder. The tumour is carefully removed, usually using an electrical or bipolar resection system.

There is therefore generally no external incision or abdominal scar.

Why obtaining bladder muscle matters

An adequate TURBT should establish how deeply the tumour extends.

For many tumours, particularly T1 and high-grade lesions, the specimen should contain muscularis propria (detrusor muscle) so that the pathologist can determine whether the cancer has reached the muscle layer. The pathological report should document the presence and involvement of muscularis propria where applicable.

This distinction dramatically changes treatment.

Understanding bladder cancer staging

A simplified view of the bladder wall is:

Urine

↓

Urothelium

↓

Lamina propria

↓

Detrusor muscle

↓

Fat surrounding the bladder

The important early stages are:

Ta

The tumour is confined to the urothelial surface and has not invaded the supporting tissue underneath.

Tis: carcinoma in situ

CIS is a flat, high-grade malignant lesion confined to the urothelium.

Unlike the typical papillary bladder tumour, CIS may be difficult to identify visually.

Despite being superficial anatomically, CIS is biologically aggressive and requires appropriate treatment.

T1

The tumour has invaded into the lamina propria, but has not invaded the muscularis propria.

T1 disease, particularly high-grade T1 disease, carries a greater risk of recurrence and progression.

T2

The cancer has invaded the bladder muscle.

Once muscle invasion is identified, the disease is no longer classified as NMIBC and requires a different treatment pathway.

Stage and grade are not the same thing

This distinction frequently causes confusion.

Stage describes how deeply the cancer has travelled into the bladder wall.

Grade describes how abnormal and biologically aggressive the cancer cells appear under the microscope.

A tumour may therefore be superficial but still be high grade.

Broadly, urothelial tumours are classified as:

Low grade

These generally grow more slowly and have a relatively low risk of progressing to muscle-invasive cancer, although they may recur.

High grade

These cells look significantly abnormal and have a greater potential for:

  • recurrence
  • invasion
  • progression
  • spread beyond the bladder

Risk stratification

Following TURBT, the tumour is classified into a risk category.

Risk assessment considers factors such as:

  • stage
  • grade
  • tumour size
  • number of tumours
  • previous recurrence rate
  • presence of CIS
  • T1 disease
  • pathological features including lymphovascular invasion
  • certain variant histological subtypes

This classification helps determine whether the patient requires:

TURBT alone → intravesical chemotherapy → BCG → or, in selected very-high-risk situations, consideration of radical cystectomy.

Modern guidelines emphasise risk-adapted rather than one-size-fits-all management.

Do I need another TURBT?

Sometimes.

A second-look or re-staging TURBT may be recommended when:

  • the initial tumour was incompletely removed
  • adequate muscle was not present in an important specimen
  • high-grade disease is present in selected circumstances
  • T1 disease is identified
  • there is concern that the original tumour may have been understaged
  • certain variant histologies are identified

The aim is to ensure that residual tumour has not been left behind and, crucially, that muscle-invasive disease has not been missed.

Intravesical treatment

Intravesical simply means that medication is placed directly into the bladder through a catheter.

This allows the treatment to come into direct contact with the bladder lining while reducing systemic exposure compared with intravenous chemotherapy.

Two important treatments are:

Mitomycin C

and

BCG

They are not interchangeable and are used for different risk groups.

Intravesical Mitomycin C

Mitomycin C is a chemotherapy drug that can be placed directly into the bladder.

Immediate Mitomycin C following TURBT

For appropriate patients with suspected low- or intermediate-risk NMIBC, a single postoperative instillation of intravesical chemotherapy may be given soon after TURBT.

Current guidelines recommend that, when used, the immediate instillation should generally occur within 24 hours of TURBT.

Its purpose is to destroy microscopic tumour cells remaining in the bladder and tumour cells released during the resection.

This reduces the risk of recurrence.

When should immediate Mitomycin C be avoided?

It should generally not be administered if there is:

  • suspected bladder perforation
  • significant bleeding requiring bladder irrigation
  • an extensive or very deep resection where perforation is a concern

This is important because chemotherapy leaking outside the bladder can cause significant local tissue injury.

Further courses of intravesical chemotherapy

Selected patients with recurrent or intermediate-risk low-grade NMIBC may receive a course of intravesical chemotherapy rather than simply a single postoperative dose.

The exact drug, schedule and duration depend upon the tumour risk profile and local treatment protocols.

Side effects of intravesical Mitomycin C

Most patients tolerate treatment reasonably well.

Possible side effects include:

  • urinary frequency
  • urgency
  • burning
  • bladder discomfort
  • haematuria
  • chemical cystitis
  • skin irritation if the medication contacts the genital skin

Rarely, severe bladder inflammation or tissue injury can occur.

Intravesical BCG

BCG stands for Bacillus Calmette-Guérin.

Yes, it originated as a tuberculosis vaccine. In the bladder it performs a completely different job.

BCG stimulates a powerful local immune response against urothelial cancer cells and remains one of the most effective bladder-preserving treatments for high-risk NMIBC.

Who should receive BCG?

BCG is principally considered for patients with:

  • high-grade Ta tumours
  • high-grade T1 tumours
  • carcinoma in situ
  • other appropriately selected high-risk or intermediate-risk NMIBC

For high-risk NMIBC, full-dose BCG with maintenance treatment for one to three years remains a guideline-supported treatment, while immediate radical cystectomy should also be discussed in appropriate high-risk and particularly very-high-risk disease.

How is BCG given?

BCG is inserted into the bladder through a small catheter.

A typical induction course consists of:

One treatment per week for six weeks.

The solution is retained within the bladder for a prescribed period and then passed out in the urine.

Patients who respond may subsequently receive maintenance BCG.

A commonly used maintenance approach involves three weekly treatments at defined intervals after induction. In high-risk disease, guideline schedules may continue maintenance for up to three years depending upon tumour risk, treatment tolerance and BCG availability.

When should BCG not be given?

BCG is a live attenuated organism and must be administered carefully.

Treatment should generally be postponed in patients with:

  • visible haematuria
  • symptomatic urinary tract infection
  • traumatic catheterisation
  • very recent TURBT

The EAU lists the first two weeks following TURBT, visible haematuria, traumatic catheterisation and symptomatic urinary infection as absolute contraindications to an intravesical BCG instillation.

Side effects of BCG

A degree of bladder irritation is common.

Patients may experience:

  • frequency
  • urgency
  • burning
  • bladder discomfort
  • mild haematuria
  • fatigue
  • low-grade fever
  • flu-like symptoms

These symptoms usually settle.

Rarely, BCG can cause a more significant systemic infection or inflammatory reaction.

Persistent high fever, chills, marked deterioration or severe illness following BCG requires urgent medical assessment.

What if BCG does not work?

Persistent or recurrent high-grade cancer despite adequate BCG treatment requires careful reassessment.

This situation should not simply be managed by repeatedly giving more BCG indefinitely.

Patients meeting criteria for BCG-unresponsive NMIBC should be counselled regarding further treatment, and radical cystectomy remains the oncological standard for suitable patients with BCG-unresponsive high-risk disease. Bladder-preserving alternatives may be considered for patients who are medically unsuitable for cystectomy or decline surgery, ideally within appropriate specialist or clinical-trial pathways.

When should radical cystectomy be considered?

Most patients with superficial bladder cancer will never require removal of their bladder.

However, early radical cystectomy may be discussed for very-high-risk disease, including selected patients with:

  • aggressive high-grade T1 disease
  • associated CIS
  • variant histology
  • lymphovascular invasion
  • persistent high-grade disease
  • BCG-unresponsive disease
  • other features associated with a high risk of progression

The decision involves balancing the risks of major surgery against the danger of allowing biologically aggressive disease to progress.

Surveillance after treatment

Removing the tumour is only the first chapter.

NMIBC has a significant tendency to recur, and some high-risk tumours can progress. Consequently, regular cystoscopic surveillance is essential.

The first surveillance cystoscopy is generally performed approximately three months after TURBT.

After this, surveillance is tailored to the patient’s risk category.

A practical risk-adapted surveillance framework

Risk group Typical cystoscopy schedule Cytology Upper tract imaging
Low risk 3 months, 12 months, then annually Usually not routinely required Not routinely required
Intermediate risk 3 months, then approximately every 6 months for 2 years, then annually Risk-dependent Selected patients
High / very high risk Approximately every 3 months initially, with intervals gradually extended Usually included Periodic upper urinary tract imaging

The 2026 EAU guidance continues to recommend that follow-up intensity and duration be determined by the patient’s risk category, with the first cystoscopy at three months.

Individual surveillance schedules may differ depending on pathology, previous recurrences, treatment response, age, comorbidities and the treating urologist’s protocol.

Why is surveillance so important?

A recurrence does not automatically mean that treatment has failed or that the cancer has become life-threatening.

Low-grade papillary tumours may recur while remaining superficial and biologically low risk.

The purpose of surveillance is to identify recurrence early, while it can still be treated appropriately.

High-grade disease requires closer attention because the consequences of missing progression are considerably greater.

Can bladder cancer come back after years?

Yes.

This is why follow-up for intermediate- and particularly high-risk NMIBC can continue for many years.

The frequency of cystoscopy usually decreases when repeated examinations remain clear, but high-risk patients generally require prolonged surveillance.

What can I do after a diagnosis?

One of the most important modifiable factors is:

Stop smoking

Smoking cessation reduces exposure to the carcinogens responsible for many urothelial cancers and provides substantial additional cardiovascular, respiratory and general health benefits.

Patients should also:

  • attend every scheduled cystoscopy
  • report recurrent visible haematuria
  • complete prescribed intravesical treatment
  • report significant side effects from BCG or chemotherapy
  • maintain appropriate hydration unless medically restricted
  • discuss occupational chemical exposure where relevant

The bottom line

Non-muscle-invasive urothelial carcinoma is bladder cancer that has not invaded the muscular wall of the bladder.

The pathway typically involves:

Haematuria or urinary symptoms
↓
Urine tests + imaging
↓
Cystoscopy
↓
TURBT and pathological examination
↓
Stage + grade + risk classification
↓
Risk-adapted treatment

For some patients, TURBT followed by surveillance may be sufficient.

Others benefit from intravesical Mitomycin C or another intravesical chemotherapy to reduce recurrence.

Patients with high-grade disease, T1 cancer or CIS frequently require intravesical BCG, usually incorporating induction and maintenance treatment.

Very-high-risk or BCG-unresponsive disease may require consideration of radical cystectomy.

Most importantly, bladder cancer treatment does not finish when the initial tumour has been removed. Long-term cystoscopic surveillance is an integral part of treatment.

A final word

Bladder cancer can be a persistent visitor, but surveillance means we do not leave the front door unattended.

Early detection, complete TURBT, accurate pathological staging, appropriate intravesical therapy and structured follow-up provide the best opportunity to keep non-muscle-invasive bladder cancer under control.

This information is intended as general patient education and does not replace individual assessment or treatment advice from your urologist. Management should be tailored to the pathology, tumour risk category, general health and individual circumstances of each patient.

Urodynamic Studies: Understanding How Your Bladder Works

/0 Comments/in , /by

Bladder problems are not always as straightforward as they appear.

Two people may both complain of urinary urgency, leakage or difficulty emptying their bladder, yet the underlying causes can be completely different. One bladder may be contracting when it should be relaxing, another may not contract strongly enough, and sometimes the bladder is behaving perfectly well while the outlet is causing all the trouble.

This is where urodynamic studies, often simply called urodynamics, can help.

Think of urodynamics as a stress test for the bladder. Rather than simply looking at its anatomy, we observe how the bladder fills, stores urine and empties while simultaneously measuring pressures, urine flow and sometimes pelvic floor activity.

The aim is not merely to produce a collection of colourful graphs. The important question is:

What is the bladder actually doing, and will knowing this change the treatment?

What Are Urodynamic Studies?

Urodynamics refers to a group of tests that assess the function of the bladder, urethra and urinary sphincter.

Depending on the clinical situation, testing may evaluate:

  • How much urine the bladder can comfortably hold
  • Bladder sensation during filling
  • Whether the bladder remains relaxed while filling
  • Whether involuntary bladder contractions occur
  • Whether urinary leakage occurs and why
  • The pressure required to store urine
  • The strength of the bladder muscle during urination
  • Whether there is obstruction to urinary flow
  • Whether the bladder empties completely
  • How the urinary sphincter and pelvic floor behave during filling and voiding

Urodynamics therefore investigates function rather than simply structure.

An ultrasound or cystoscopy may show us what the urinary tract looks like. Urodynamics tells us what it is doing.

Who May Need Urodynamic Testing?

Not every patient with urinary symptoms requires urodynamics.

For many straightforward urinary problems, the diagnosis can be made from the history, examination, bladder diary, urine testing, flow studies and ultrasound.

Urodynamics becomes particularly useful when the diagnosis is uncertain, symptoms are complex, previous treatments have failed, neurological disease is present, or an invasive treatment is being considered where understanding bladder function may alter the choice of treatment.

Common indications include:

Urinary Incontinence

Urodynamics may be useful when assessing:

  • Stress urinary incontinence
  • Urgency urinary incontinence
  • Mixed urinary incontinence
  • Persistent leakage following previous continence surgery
  • Incontinence following prostate surgery
  • Complex or unexplained urinary leakage

In straightforward female stress urinary incontinence, urodynamics is not necessarily required before treatment. It becomes more useful when symptoms and clinical findings do not agree or when there are complicating factors.

Overactive Bladder

Patients with overactive bladder may experience:

  • Urinary urgency
  • Frequent urination
  • Nocturia
  • Urgency urinary incontinence

Urodynamics can sometimes demonstrate detrusor overactivity, where the bladder muscle contracts involuntarily during filling.

Importantly, a normal urodynamic study does not necessarily exclude overactive bladder. Symptoms and urodynamic findings do not always travel together.

Difficulty Emptying the Bladder

Patients may report:

  • Poor urinary flow
  • Hesitancy
  • Straining
  • Intermittent flow
  • Incomplete emptying
  • Urinary retention

The challenge is determining why.

Is there an obstruction?

Or is the bladder muscle simply not contracting strongly enough?

The symptoms can look remarkably similar, but the treatments can be very different.

Men With Lower Urinary Tract Symptoms

In men with prostate enlargement, urodynamics may help distinguish between:

Bladder outlet obstruction

and

Detrusor underactivity, where the bladder muscle has insufficient strength to empty effectively.

This distinction may be particularly valuable before prostate surgery when there is uncertainty about whether removing the obstruction will improve urinary flow.

Neurological Bladder Dysfunction

Urodynamics has an especially important role in patients with neurological conditions such as:

  • Spinal cord injury
  • Multiple sclerosis
  • Parkinson’s disease
  • Spina bifida
  • Stroke
  • Certain spinal disorders

In these patients, we are interested not only in urinary symptoms but also in whether bladder pressures could potentially damage the kidneys.

Before or After Certain Urinary Procedures

Urodynamics may also be considered:

  • Before complex continence surgery
  • Following unsuccessful continence surgery
  • Before some bladder outlet procedures
  • Following prostate surgery when symptoms persist
  • When considering treatments such as bladder Botox or sacral neuromodulation in selected complex patients

What Happens During a Urodynamic Study?

The test is usually performed as an outpatient procedure.

It generally takes approximately 30–60 minutes, although this varies depending on the type of study being performed.

You can usually eat, drink and take your normal medications unless specifically instructed otherwise.

Step 1: Arriving With a Comfortably Full Bladder

You may be asked to arrive with a reasonably full bladder.

You will urinate into a special toilet called a uroflowmeter.

This measures:

  • Urine volume
  • Maximum urinary flow rate
  • Average flow rate
  • The shape of the urinary flow curve
  • How long urination takes

An ultrasound may then measure how much urine remains in the bladder.

This is called the post-void residual.

Step 2: Placement of Small Catheters

A very fine catheter is gently passed through the urethra into the bladder.

A second small pressure catheter is usually placed into the rectum, or occasionally the vagina.

Why two pressure measurements?

Because pressure inside the abdomen affects pressure inside the bladder.

By measuring both, the computer can calculate the pressure generated specifically by the bladder muscle:

Detrusor pressure = bladder pressure − abdominal pressure

This simple equation sits at the heart of conventional urodynamics.

Step 3: Filling the Bladder

The bladder is slowly filled with sterile fluid.

During filling, you will be asked to describe what you feel.

We may record:

  • First sensation of bladder filling
  • First desire to urinate
  • Strong desire to urinate
  • Maximum bladder capacity

The pressure inside the bladder is continuously monitored.

Normal filling cystometrogram

https://images.openai.com/static-rsc-4/Hgriy5E9FGtRilFNQh3tQE53yrlbWRzHlZE-lg73YC5P10G0EFIrVgMREqgOL5uEui9m4vTZQa3aZdbm2IQos6eTVRAdTIXlg1d841nyByIJ3GZk8QFyf9avtCBCjESBk_UcSEGbJGzOSIvZvPI6wZtNpz7LHnbB3kQIYDHsibqiwXmWpERNixUhOeW6Tm2B?purpose=fullsize
https://images.openai.com/static-rsc-4/BXwVAcldUDjh2tAaV2En87FX0ONS1oomHAkm4Z6BLZyoexIiDmaACUh8t4rB7TDfao-guZf76ULaTYX-VsV554nagvCAPRpNzs7HNQvKKZYuX8N6oPO5c_n_74de2tABnoEt69kwxCY_fJyF86M5rduxVEOG1zrNzm0SXMSrnXPiadRMzOfo1hPUnKvP1ahH?purpose=fullsize
https://images.openai.com/static-rsc-4/ySZcZmtN_5IZCgz4scVLbu2KqbZD3OVebnVIjG7F41-xqaWl2-D1RqW5T2NMWjugPRIkt7H-S3JB2UGWLPXIYYyURXURsMwzaASQ1zMpc7f1yB8UJcFDYMc1HW3qPkSw7rWCM7V8cMPh-oI2CVWQYD1HhlPxcJ6eJY6HJvYEz3QSK5VgEbfQgqejsiCVUfkK?purpose=fullsize
4

Normal filling cystometrogram. During filling, the bladder accommodates increasing volume while detrusor pressure (Pdet) remains relatively stable. Coughs cause corresponding rises in Pves and Pabd without a true detrusor contraction. Sensations such as first sensation, first desire and strong desire can be marked on the tracing.

 

Step 4: Provocative Testing

You may be asked to:

  • Cough
  • Strain
  • Stand
  • Change position
  • Listen to running water

These manoeuvres are not designed to make the test unnecessarily theatrical. They help reproduce the circumstances under which your symptoms normally occur.

If urinary leakage occurs during coughing without an involuntary bladder contraction, this may demonstrate urodynamic stress incontinence.

Step 5: Voiding

Once the bladder is comfortably full, you will be asked to urinate.

During urination we simultaneously measure:

  • Urinary flow
  • Bladder pressure
  • Abdominal pressure
  • Detrusor pressure

This is called a pressure-flow study.

It can be extremely useful when determining whether poor urinary flow is caused by obstruction or weak bladder contraction.

What Does Urodynamics Measure?

Bladder Sensation

We assess when you first become aware that the bladder is filling and when the desire to urinate becomes stronger.

Sensation may be:

  • Normal
  • Increased
  • Reduced
  • Absent

Abnormal bladder sensation may occur in several neurological and functional bladder disorders.

Bladder Capacity

The amount of urine the bladder can comfortably hold is measured.

A small functional capacity may occur with conditions such as severe urgency or bladder hypersensitivity, although capacity must always be interpreted in clinical context.

Bladder Compliance

A healthy bladder should behave rather like a flexible reservoir.

As it fills, its volume should increase without a major rise in pressure.

Poor bladder compliance means pressure rises excessively as the bladder fills.

This is particularly important in some neurological bladder disorders because persistently elevated storage pressures can potentially threaten the upper urinary tract.

Detrusor Overactivity

If the bladder muscle contracts involuntarily during filling, this is called:

Detrusor overactivity.

It may be associated with:

  • Urgency
  • Urgency incontinence
  • Frequency
  • Nocturia

When associated with an underlying neurological condition, it may be described as neurogenic detrusor overactivity.

Examples of terminal, phasic, wet and dry detrusor overactivity.

https://images.openai.com/static-rsc-4/Snzbj3YLBffWTq3-7c6jgZQWHTjwV03Siqh8rQZor7nWrcUTSujo5I4h9H6QmPWIw5TQO8oSYgzzugdooybbroYfbxONiyj0mx1Qe1uBjCwkL4K0AR5hGhULd9PKwFrw7LhUIrL8ZxpKQO1sQjk0qtqph3By5IOK30vdjd9Iahom6SUGG32ajdo2KW48nbhP?purpose=fullsize
https://images.openai.com/static-rsc-4/kx0pZHTOwdE7kDcSE1Awe3tnf1oB9kJizr_DFgQV0kdb9o6N2KxN9PW2lGCO4Rxcyx__zDzECnRwDhOrCXcXYbHZKkw4yASruDH4PtFNhlq6LqHzLF1d6NmcZkyOnoMHG_lNoKxw1Y5hCVuog5TIJqiN5O_zT8m7FtEhZkE-uHlwJMGAWpqcUhXKZdvq-h6c?purpose=fullsize
https://images.openai.com/static-rsc-4/9Fkv2MrdLw18QItSBrvBMWrFM_bRYOzwvod8KcVnSNQcBgQhcEl7m90lhNqlnqb3sX1pkEmdrx3XvCJxwi0gyzVvPse-T2lyODyK7BrW5xC3GJ2ZMggrrj7i-iArmLIQ05FXaE_4Cl8FYZ8yrU3dqXP5YN2gEVqQjCLOqH_xcbXAxuyLiYNLNijADJM9eUNR?purpose=fullsize

Detrusor overactivity. During bladder filling there is an involuntary increase in Pdet that cannot be explained by a corresponding increase in abdominal pressure. The contraction may be associated with urgency and, when leakage occurs, urgency urinary incontinence.

View the LABORIE-based detrusor-overactivity tracings

Stress Urinary Incontinence

If urine leaks when coughing or straining without a detrusor contraction, this supports a diagnosis of:

Urodynamic stress incontinence.

Additional measurements such as leak-point pressures may occasionally contribute to assessment in selected patients.

Bladder Outlet Obstruction

During urination, a pattern of:

High bladder pressure + low urinary flow

may suggest obstruction.

In men, benign prostate enlargement is a common cause.

Other causes include:

  • Urethral stricture
  • Bladder neck obstruction
  • Previous continence surgery
  • Dysfunctional voiding

Bladder outlet obstruction: pressure-flow study

https://images.openai.com/static-rsc-4/Efx8v2pSLdy0yriNx_qrcdTAHacUkb8mu_Sb7IjS9JvC0wxMQnPCPhcGQqAt0MQUNQ5jvnXe4yfU0qsIfsNRYrR7VLV4HhGFH6Ko01-kkE8GfSflqXD25Q6gkF3bmxyKYN9iYNHRqCJ0bV-igYyNfPP-21Nuvrls3kleV1a2fqsUDDQTALKE8mVkjEwglUbr?purpose=fullsize
https://images.openai.com/static-rsc-4/tQjdaSX6-MApQNNeYZuCDcT--H0Z_StPvpdtjnAdqL29pMWjRBGXsV_1KAe9iBU0kahuMqsxvNOoXDeZHFfSLBLxXg9w9uWzWnQxuEBsHfk3yjNkiDLedV-AQMJTHLPoif8aUAghyfhiv605EryWDjmBxVWKeBTNK3ky_okFHyRdz9rN1G-HNnhJBUnvnQhG?purpose=fullsize

Bladder outlet obstruction. During voiding the bladder generates a relatively high detrusor pressure, but urinary flow remains reduced. This high-pressure, low-flow relationship is characteristic of increased bladder outlet resistance.

In men, pressure-flow studies allow calculation of the Bladder Outlet Obstruction Index (BOOI):

BOOI = PdetQmax − 2(Qmax)

For men, BOOI >40 is generally classified as obstructed, 20–40 as equivocal and <20 as unobstructed.

Detrusor Underactivity

Sometimes the urinary flow is poor because the bladder muscle does not generate sufficient pressure.

This is known as:

Detrusor underactivity.

This distinction matters.

Operating on the prostate of a patient whose main problem is a very weak bladder may not produce the expected improvement in urinary flow.

Urodynamics can therefore occasionally prevent us from treating the wrong end of the plumbing.

Dysfunctional Voiding

Some patients involuntarily contract their pelvic floor or urinary sphincter while attempting to urinate.

Instead of the outlet opening smoothly, it intermittently closes.

Pelvic floor electromyography may help identify this pattern in selected patients.

Understanding the Urodynamic Tracing

A urodynamic report typically contains several pressure and flow curves.

At first glance, the tracing can resemble an enthusiastic seismograph.

The important measurements usually include:

Pves: pressure measured inside the bladder.

Pabd: pressure measured within the abdomen.

Pdet: pressure generated by the bladder muscle.

Flow: the rate at which urine leaves the bladder.

The relationship between these measurements allows us to understand what is happening during bladder filling and emptying.

Common Findings and What They May Mean for Treatment

Urodynamic Finding Possible Interpretation Potential Treatment Direction
Normal storage and emptying Normal urodynamic study Treatment guided by symptoms and other investigations
Detrusor overactivity Overactive bladder physiology Bladder training, medication, Botox, neuromodulation
Stress leakage Stress urinary incontinence Pelvic floor therapy, bulking agents, sling or other continence surgery
High pressure + low flow Bladder outlet obstruction Treatment of obstruction where appropriate
Low pressure + low flow Detrusor underactivity Emptying strategies, intermittent catheterisation or selected treatments
Poor compliance High-pressure storage Pressure-reducing treatment and upper urinary tract surveillance
Pelvic floor activation during voiding Dysfunctional voiding Pelvic floor physiotherapy/biofeedback
Significant residual urine Incomplete bladder emptying Identify obstruction versus impaired bladder contraction

The urodynamic result is not a treatment plan by itself.

It must be interpreted alongside symptoms, examination findings, bladder diaries, ultrasound, cystoscopy and other investigations where appropriate.

How Urodynamics Can Guide Treatment

If Detrusor Overactivity Is Found

Initial treatment may include:

  • Bladder training
  • Fluid modification
  • Pelvic floor physiotherapy
  • Antimuscarinic medication
  • Beta-3 agonist medication

For persistent symptoms, options may include:

  • Intravesical Botox injections
  • Sacral neuromodulation
  • Other specialist treatments in selected patients

If Stress Incontinence Is Demonstrated

Treatment depends on severity, sex, previous surgery and individual circumstances.

Options may include:

  • Pelvic floor rehabilitation
  • Continence devices
  • Peri-urethral bulking agents
  • Sling procedures
  • Colposuspension in selected women
  • Male sling following prostate surgery
  • Artificial urinary sphincter in appropriate men

If Bladder Outlet Obstruction Is Demonstrated

Treatment depends on the underlying cause.

For benign prostate enlargement, options may include:

  • Medication
  • Minimally invasive prostate treatments
  • Laser prostate surgery
  • Transurethral prostate surgery
  • Other surgical procedures appropriate to prostate size and anatomy

A urethral stricture or bladder neck obstruction requires a different treatment strategy.

If the Bladder Muscle Is Weak

Treatment may involve:

  • Double voiding
  • Timed voiding
  • Reviewing medications
  • Treating reversible causes
  • Intermittent self-catheterisation when necessary
  • Long-term catheterisation in selected circumstances
  • Sacral neuromodulation in carefully selected patients with non-obstructive urinary retention

The key issue is avoiding unnecessary outlet surgery when obstruction is not actually the problem.

If Bladder Storage Pressures Are High

This is particularly important in neurological bladder disease.

Treatment may include:

  • Medication
  • Intermittent catheterisation
  • Intravesical Botox
  • Regular renal imaging
  • Monitoring kidney function
  • Repeat urodynamic assessment
  • Reconstructive bladder surgery in uncommon severe cases

Here the objective extends beyond improving symptoms. We may also be trying to protect kidney function over the long term.

Are Urodynamic Studies Uncomfortable?

Most patients tolerate the investigation well.

Passing the small catheter can cause brief discomfort, and there may be some mild burning when urinating afterwards.

Having an audience while your bladder performs under laboratory conditions is admittedly not anyone’s preferred afternoon entertainment, but the clinical staff performing these studies do this routinely and will make the process as private and comfortable as possible.

Possible Side Effects and Complications

Urodynamic testing is generally safe.

Possible side effects include:

  • Temporary burning during urination
  • Urinary urgency
  • Minor urethral discomfort
  • A small amount of blood in the urine
  • Urinary tract infection
  • Temporary difficulty urinating

Significant complications are uncommon.

Patients should seek medical advice if they develop fever, chills, worsening urinary symptoms, significant bleeding or an inability to urinate following the test.

Does Everyone With Bladder Symptoms Need Urodynamics?

No.

This is an important point.

Urodynamics should generally be performed when the result is likely to answer a clinically relevant question or potentially alter management.

The investigation is particularly valuable when:

  • Symptoms are complex
  • The diagnosis remains uncertain
  • Symptoms and examination findings disagree
  • Previous treatment has failed
  • Neurological bladder dysfunction is suspected
  • There is significant urinary retention
  • Complex surgery is being considered
  • Understanding bladder pressure or contractility could change treatment

Testing simply because “we haven’t done one yet” is not a particularly compelling indication.

Urodynamics: Turning Symptoms Into Physiology

Patients often arrive describing urgency, leakage, poor flow or difficulty emptying their bladder.

These symptoms tell us what is happening.

Urodynamics can sometimes tell us why.

By measuring how the bladder stores and releases urine, we can distinguish between problems involving the bladder muscle, urinary sphincter, pelvic floor and bladder outlet.

Most importantly, urodynamics can help ensure that treatment is directed at the underlying problem rather than simply the symptom.

The Bottom Line

Urodynamics is not necessary for every bladder problem. But when the diagnosis is uncertain or treatment decisions depend on understanding bladder function, it can provide exceptionally useful information.

A good urodynamic study does more than generate graphs.

It helps answer the question that matters most:

What treatment is most likely to work for this particular bladder?

This information is intended for general patient education and does not replace individual medical assessment. The need for urodynamic testing and interpretation of results should be discussed with your treating urologist or continence specialist.

The Long Foreskin: When a Little Extra Skin Is Just… Extra

/0 Comments/in , /by

Foreskins come in all shapes and sizes. Some are short, some sit neatly over the tip of the penis, and others extend well beyond the glans, occasionally giving the penis the appearance that it has ordered the extra-long sleeve option.

A long foreskin, sometimes described medically as a redundant or elongated prepuce, is usually simply a normal anatomical variation. Length alone is not a disease and does not automatically require treatment.

The important question is not “How long is it?” but rather:

Does it cause any problems?

What is a long or redundant foreskin?

The foreskin, or prepuce, is the fold of skin covering the glans (head) of the penis. Its length varies considerably between men.

In some men, the foreskin extends only slightly beyond the glans when the penis is flaccid. In others, there may be a considerable amount of skin extending beyond the tip.

The appearance can also change substantially between the flaccid and erect states. A foreskin that looks impressively generous when flaccid may retract quite normally during an erection.

There is therefore no particular measurement at which a foreskin suddenly becomes “too long.”

If it retracts comfortably, causes no symptoms and can be kept clean, there is generally no medical reason to shorten it.

Can a very long foreskin cause problems?

Most men with a long foreskin have no problems whatsoever.

Occasionally, however, additional foreskin can contribute to several issues.

Hygiene

A longer foreskin may make cleaning beneath the foreskin slightly more important.

Smegma, dead skin cells and moisture can accumulate underneath the foreskin if it is not regularly retracted and washed. This may produce irritation or an unpleasant smell.

Fortunately, the solution is usually wonderfully low-tech: water, gentle washing and regular hygiene.

Aggressive scrubbing, strong soaps, antiseptics and fragranced products can actually irritate this rather sensitive real estate.

Recurrent balanitis

Balanitis is inflammation of the glans. When both the glans and foreskin are inflamed, the condition is called balanoposthitis.

Symptoms may include:

  • Redness
  • Swelling
  • Itching or burning
  • Discomfort
  • Discharge
  • Unpleasant odour
  • Difficulty retracting the foreskin

Recurrent inflammation deserves assessment because there may be an underlying cause such as infection, dermatitis, diabetes or a chronic inflammatory skin condition.

Difficulty retracting the foreskin

A long foreskin and a tight foreskin are not the same thing.

A very long foreskin that retracts easily is generally harmless. If the opening is too narrow to retract comfortably over the glans, however, this is phimosis.

Phimosis can cause discomfort, recurrent infections, painful erections or difficulty with sexual activity.

Paraphimosis

Occasionally a tight foreskin is pulled behind the glans and becomes trapped there. The foreskin swells and cannot be returned to its normal position.

This is called paraphimosis.

Unlike having a long foreskin, paraphimosis is not merely an interesting anatomical conversation starter. It can compromise blood flow to the glans and requires urgent medical attention.

Problems during sex

Some men with considerable redundant foreskin notice excessive movement or bunching of the skin during intercourse.

Others experience:

  • Irritation
  • Small tears
  • Discomfort
  • Difficulty using condoms
  • Foreskin becoming trapped behind the glans
  • Problems associated with an accompanying short frenulum

Importantly, many men with long foreskins have completely normal and comfortable sexual function.

Urination

A long foreskin may occasionally balloon during urination or cause the urinary stream to spray.

A little post-urination dribbling from urine retained beneath a long foreskin can also occur.

If the foreskin opening is normal and there are no other symptoms, this is often more inconvenient than medically significant. Persistent ballooning associated with a very narrow opening, pain or difficulty passing urine should be assessed.

Does a long foreskin increase the risk of cancer?

Having a long foreskin by itself does not mean that a man will develop penile cancer.

Penile cancer is uncommon, particularly in Australia. Important risk factors include persistent HPV infection, smoking, chronic inflammation and certain foreskin disorders such as lichen sclerosus.

Any persistent penile ulcer, lump, thickened area, bleeding lesion, unusual discharge or change in the skin should therefore be examined rather than waiting for it to disappear.

The penis, regrettably, has never been particularly good at diagnosing itself.

Does a long foreskin need treatment?

Usually, no.

If the foreskin:

  • Retracts comfortably
  • Can be cleaned easily
  • Does not cause recurrent infections
  • Does not interfere with urination
  • Does not cause pain during erections or intercourse
  • Does not bother the patient cosmetically

then no treatment is required.

The medical principle here is refreshingly simple:

If it isn’t causing a problem, there may be nothing to fix.

Conservative management

When symptoms are minor, treatment may involve improving foreskin hygiene and treating any underlying inflammation or infection.

Where there is associated mild phimosis, a doctor may recommend a course of topical corticosteroid cream combined with gentle stretching.

Forceful stretching should be avoided. Small tears can produce scarring, and scarring can make the foreskin progressively tighter, turning a relatively minor problem into a considerably more stubborn one.

Surgical options

Surgery may be considered when there are significant or recurrent problems.

Circumcision

Circumcision removes the foreskin and permanently exposes the glans.

It is a reliable treatment for recurrent balanitis, troublesome phimosis and certain chronic foreskin diseases.

Potential complications include bleeding, infection, altered sensation, cosmetic dissatisfaction, wound problems and, rarely, more significant complications.

Foreskin-preserving surgery

Not every foreskin problem requires complete circumcision.

Depending upon the anatomy and underlying problem, procedures such as preputioplasty can widen a tight foreskin while preserving much of the foreskin.

In selected men with excessive redundant skin but an otherwise healthy foreskin, surgical shortening may also be discussed.

The appropriate operation depends upon the reason for treatment rather than simply the number of centimetres of foreskin involved.

What about appearance?

Some men simply dislike having a long foreskin.

That is a legitimate concern to discuss with a urologist, but cosmetic surgery deserves careful consideration because surgery permanently changes normal anatomy.

It is particularly important to distinguish between a genuinely troublesome anatomical issue and anxiety created by comparisons with pornography, photographs or other men.

There is an enormous range of normal penile anatomy.

Normal does not come in one factory setting.

When should you see a urologist?

Consider seeking medical advice if you have recurrent infections, difficulty retracting or replacing the foreskin, painful erections, tearing or bleeding, problems during intercourse, difficulty passing urine, persistent skin changes or simply uncertainty about whether your foreskin is normal.

A foreskin that suddenly becomes swollen and trapped behind the glans requires urgent assessment, particularly if the glans becomes increasingly swollen, painful or discoloured.

The bottom line

A very long foreskin is usually a variation of normal anatomy rather than a medical condition.

There is no prize for having the shortest foreskin, and fortunately no excess-baggage fee for having the longest.

What matters is function.

If your foreskin retracts normally, stays healthy, allows comfortable erections and intercourse, and can be kept clean, its length alone is unlikely to require treatment.

If it becomes tight, painful, repeatedly inflamed or simply troublesome, however, a urological assessment can determine whether conservative treatment or surgery is appropriate.

When it comes to foreskins, longer isn’t necessarily better or worse. Sometimes it is simply… longer.

Vasectomy: A Guide to Permanent Male Contraception

/0 Comments/in , /by

Vasectomy is a safe, effective and permanent method of male contraception. It is a relatively minor surgical procedure that prevents sperm from entering the semen by interrupting the vas deferens, the tubes that carry sperm from the testicles.

For men and couples who are confident that their family is complete, vasectomy provides highly reliable contraception without the need for ongoing medication or contraceptive devices.

What Happens During a Vasectomy?

Sperm are produced in the testicles and mature within the epididymis. During ejaculation, sperm normally travel through a tube called the vas deferens, where they ultimately mix with fluid produced by the prostate and seminal vesicles to form semen.

During a vasectomy, each vas deferens is divided and sealed so that sperm can no longer reach the ejaculate.

Importantly, vasectomy does not stop the testicles from producing sperm. The sperm that continue to be produced are naturally broken down and absorbed by the body.

Who Should Consider a Vasectomy?

Vasectomy may be appropriate for men who:

  • Have completed their family and do not want more children.
  • Do not wish to have children in the future.
  • Want a highly effective permanent form of contraception.
  • Have a partner for whom pregnancy would represent a significant health risk.
  • Prefer male sterilisation rather than their partner undergoing a more invasive sterilisation procedure.
  • Wish to avoid the need for long-term hormonal or barrier contraception.

The most important consideration is that vasectomy should be regarded as permanent.

Although vasectomy reversal is possible, successful reversal cannot be guaranteed. Men who are uncertain about future fertility should carefully consider alternative contraception or, in selected circumstances, sperm banking before proceeding.

How Is Vasectomy Performed?

Vasectomy is usually performed as a day procedure, commonly under local anaesthetic, although sedation or general anaesthesia may occasionally be appropriate.

A conventional or no-scalpel technique may be used.

The vas deferens is identified through a small opening in the scrotal skin. A short segment of the vas may be removed, and the divided ends are then sealed using techniques such as cautery, ligation and/or fascial interposition.

The procedure generally takes approximately 15–30 minutes.

Patients are usually able to return home shortly afterwards.

What Should I Expect After the Procedure?

Mild discomfort, bruising and swelling of the scrotum are common during the first few days.

Simple measures can help recovery, including:

  • Wearing supportive underwear.
  • Using simple analgesia as recommended.
  • Avoiding strenuous physical activity and heavy lifting for several days.
  • Keeping the wound clean and dry according to your surgeon’s instructions.
  • Avoiding sexual activity until discomfort and swelling have settled.

Most men can return to sedentary work relatively quickly, while men involved in heavy physical work may require a longer recovery period.

Vasectomy Does Not Work Immediately

This is one of the most important facts to understand about vasectomy.

A man is not sterile immediately after the procedure.

Sperm that were already present beyond the site of the vasectomy may remain within the reproductive tract for a period after surgery.

For this reason, another reliable method of contraception must be used until a post-vasectomy semen analysis confirms that the procedure has been successful.

Your urologist will advise when the semen test should be performed according to the protocol being followed.

Do not stop contraception simply because a certain number of weeks or ejaculations have passed. Wait until appropriate semen testing has confirmed success.

How Effective Is Vasectomy?

Vasectomy is one of the most effective forms of contraception available.

However, no contraceptive procedure can be regarded as absolutely 100% effective. Rarely, the divided ends of the vas deferens can reconnect, a process known as recanalisation.

Recanalisation may occur early after surgery and be detected on semen testing, or very rarely occur later after an initially successful vasectomy.

This is one reason why post-vasectomy semen analysis is an essential part of the procedure rather than an optional extra.

Does Vasectomy Affect Testosterone?

No.

Vasectomy does not remove or damage the testicles, and testosterone production continues normally.

A vasectomy should therefore not cause:

  • Loss of masculinity.
  • Reduced testosterone levels.
  • Loss of facial or body hair.
  • Reduced muscle mass.
  • Premature ageing.

Does Vasectomy Affect Erections or Sexual Function?

Vasectomy does not normally affect the ability to obtain or maintain an erection.

It also does not interfere with orgasm.

The nerves and blood vessels responsible for erections are not interrupted during a routine vasectomy.

Will Ejaculation Be Different?

Most of the volume of semen comes from the prostate and seminal vesicles, rather than from sperm.

Consequently, ejaculation continues after vasectomy and the appearance and volume of the semen are generally essentially unchanged.

The difference is microscopic: once the vasectomy has been successful, sperm are no longer present in the ejaculate.

What Are the Possible Complications?

Vasectomy is generally a low-risk procedure, but complications can occur.

Bleeding and Haematoma

Bleeding into the scrotum can result in swelling, bruising or a collection of blood known as a haematoma.

Small haematomas usually settle with conservative management. Large or expanding haematomas occasionally require further treatment.

Infection

Infection of the skin or deeper scrotal tissues is uncommon but may occur. Symptoms can include increasing pain, redness, swelling, discharge or fever.

Pain and Swelling

Some degree of discomfort and swelling is expected during the initial recovery period and usually settles.

Sperm Granuloma

Sperm may occasionally leak from the divided end of the vas and produce a small inflammatory lump known as a sperm granuloma.

These are often harmless but can occasionally be tender.

Epididymal Congestion

Some men develop aching or discomfort around the epididymis following vasectomy, possibly related to pressure within the sperm-carrying system.

This is usually temporary but can occasionally persist.

Post-Vasectomy Pain Syndrome

A small proportion of men experience persistent or recurrent testicular or scrotal pain lasting for months or longer after vasectomy.

This is known as chronic post-vasectomy pain or post-vasectomy pain syndrome.

Treatment depends upon severity and may include:

  • Anti-inflammatory or pain medication.
  • Pelvic floor or other targeted therapy where appropriate.
  • Nerve-directed treatment.
  • Spermatic cord procedures.
  • Epididymectomy in selected cases.
  • Vasectomy reversal in carefully selected patients.

Further surgery is rarely required, but persistent pain is an important complication to discuss before deciding on vasectomy.

Vasectomy Failure and Recanalisation

Occasionally sperm remain present because the vas deferens has reconnected or the procedure has otherwise failed to achieve sterility.

Persistent sperm on semen analysis may require further testing and, occasionally, a repeat vasectomy.

Very rarely, late recanalisation can occur after a previously satisfactory semen analysis, meaning that pregnancy remains possible even after initial clearance.

Does Vasectomy Increase the Risk of Prostate Cancer?

Vasectomy has been extensively studied in relation to prostate cancer and other long-term health concerns.

Current evidence has not established vasectomy as a cause of prostate cancer, and vasectomy is not generally considered a reason to alter routine prostate cancer screening or assessment.

Men should continue appropriate prostate health checks based on their age, family history, symptoms and individual risk factors.

Can a Vasectomy Be Reversed?

Yes, but reversal is considerably more complex than the original vasectomy.

Vasectomy reversal involves microsurgically reconnecting the reproductive tract, usually with a vasovasostomy or, when necessary, a vasoepididymostomy.

Success depends on several factors, including:

  • The length of time since vasectomy.
  • The condition of the vas deferens and epididymis.
  • The surgical technique required.
  • The experience of the microsurgeon.
  • The fertility and age of both partners.

Successful return of sperm to the semen does not necessarily guarantee pregnancy.

For this reason, a vasectomy should never be undertaken on the assumption that it can simply be reversed later.

Alternatives to Vasectomy

Men who are uncertain about permanent contraception should consider reversible alternatives.

Depending upon individual circumstances, these may include condoms or contraceptive methods used by the female partner, including hormonal contraception, intrauterine devices and contraceptive implants.

The choice should take into account effectiveness, side effects, medical history, personal preference and future fertility plans.

When Should I Seek Medical Attention After Vasectomy?

Contact your doctor or urologist if you develop:

  • Increasing rather than improving scrotal pain.
  • Significant or rapidly increasing swelling.
  • Heavy bleeding.
  • Increasing redness or discharge from the wound.
  • Fever or feeling systemically unwell.
  • Persistent testicular pain.
  • A concerning new scrotal lump.

The Bottom Line

Vasectomy is a highly effective, relatively simple and permanent form of male contraception.

For appropriately selected men who have completed their families, it can remove the need for ongoing contraception while leaving testosterone production, erections, orgasm and ejaculation essentially unchanged.

The key points are to understand that vasectomy should be considered permanent, complications such as chronic scrotal pain and failure can occur, and the procedure does not provide immediate contraception.

Most importantly, continue contraception after vasectomy until your post-vasectomy semen analysis has confirmed that it is safe to stop.

This information is intended for general education and does not replace individual medical advice. Your urologist can discuss whether vasectomy is appropriate for you, the technique used, expected recovery and the post-vasectomy semen-testing protocol.